

Molbio Diagnostics Private Limited

Standalone Financial Statements for the year ended March 31, 2024

INDEPENDENT AUDITOR'S REPORT

To the Members of Molbio Diagnostics Private Limited

Report on the Audit of the Standalone Ind AS Financial Statements**Opinion**

We have audited the accompanying standalone Ind AS financial statements of Molbio Diagnostics Private Limited ("the Company"), which comprise the Balance sheet as at March 31 2024, the Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and notes to the standalone Ind AS financial statements, including a summary of material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone Ind AS financial statements give the information required by the Companies Act, 2013, as amended ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, its profit including other comprehensive income its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

We conducted our audit of the standalone Ind AS financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the standalone Ind AS Financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone Ind AS financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone Ind AS financial statements.

Emphasis of Matter

We draw attention to Note 6 of standalone Ind AS financial statements as regards the investment made by the Company in Prognosys Medical Systems Private Limited ('PMS') amounting to ₹ 390.71 Million during the previous year. PMS had suffered a fraud as regards misappropriation of earnest money deposits ('EMD') of ₹ 199.00 Million made by PMS prior to the investment by the Company and is taking legal recourse to recover the same. The Company is confident of recovery of the aforesaid EMD, based on the various legal actions taken by PMS and the management of the Company.

Our opinion is not modified in respect of this matter.

Information Other than the Standalone Ind AS Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's report, but does not include the standalone Ind AS financial statements and our auditor's report thereon.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

Our opinion on the standalone Ind AS financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone Ind AS financial statements, our responsibility is to read the other information and, in doing so, consider whether such other information is materially inconsistent with the standalone Ind AS financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

The Director's report is not made available to us as at the date of this Auditor's report. We have nothing to report in this regard.

Responsibility of Management for the Standalone Ind AS Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone Ind AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone Ind AS financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Ind AS Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone Ind AS financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone Ind AS financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone Ind AS financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to the standalone Ind AS financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone Ind AS financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone Ind AS financial statements, including the disclosures, and whether the standalone Ind AS financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure I" a statement on the matters specified in paragraphs 3 and 4 of the Order.
2. As required by Section 143(3) of the Act, we report, to the extent applicable, that:
 - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;
 - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except that the backup of the books of account and other books and papers maintained in electronic mode has not been maintained on server physically located in India on daily basis, and as detailed in note 47 of the standalone Ind AS financial statements for the matters stated in the paragraph (g) and paragraph (j)(vi)) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014, as amended.
 - (c) The Balance Sheet, the Statement of Profit and Loss including the Statement of Other Comprehensive Income, the Cash Flow Statement and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account;
 - (d) In our opinion, the aforesaid standalone Ind AS financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Companies (Indian Accounting Standards) Rules, 2015, as amended, specified under section 133 of the Act;



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

- (e) The matter described in the Emphasis of Matter paragraph, clause (i)(b), (iii)(a), iii(b), iii(e), (vii)(a), (ix)(d), (xi)(a), (xiv) and (xx) of "Annexure I" to this report and Disclaimer of Opinion paragraph of "Annexure II" to this report, in our opinion, may have an adverse effect on the functioning of the Company;
- (f) On the basis of the written representations received from the directors as on March 31, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2024 from being appointed as a director in terms of Section 164 (2) of the Act;
- (g) The modification relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph (b) above on reporting under Section 143(3)(b) and paragraph (j)(vi) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014, as amended;
- (h) With respect to the adequacy of the internal financial controls with reference to these standalone Ind AS financial statements and the operating effectiveness of such controls, refer to our separate Report in "Annexure II" to this report;
- (i) The provisions of section 197 read with Schedule V of the Act are not applicable to the Company for the year ended March 31, 2024;
- (j) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigations on its financial position in its standalone Ind AS financial statements – Refer note 35 to the standalone Ind AS financial statements;
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses;
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv.
 - a) The management has represented that, to the best of its knowledge and belief, other than as disclosed in the note 42(vii) to the standalone Ind AS financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - b) The management has represented that, to the best of its knowledge and belief, and as disclosed in the note 42(viii) to the standalone Ind AS financial statements, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

- c) Based on such audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.
- v. No dividend has been declared or paid during the year by the Company.
- vi. Based on our examination which included test checks and as described in note 47 to the standalone Ind AS financial statements, the Company has used an accounting software, for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software except that, audit trail feature is not enabled for certain changes made, if any using privileged/ administrative access rights. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with, in respect of accounting software where the audit trail has been enabled.

Further, based on our examination which included test checks and as explained in note 47 to the standalone Ind AS financial statements, the Company, has used an accounting software, which is operated by a third-party software service provider, for maintaining its books of account and in the absence of Service Organization Controls report we are unable to comment on whether audit trail feature of the said software was enabled and operated throughout the year for all relevant transactions recorded in the software or whether there were any instances of the audit trail feature being tampered with, in respect to an accounting software.

For **S.R. Batliboi & Associates LLP**

Chartered Accountants

ICAI Firm Registration Number: 101049W/E300004


per **Sandeep Karnani**

Partner

Membership Number: 061207

UDIN: 24061207BKBJYZ3401

Place of Signature: Bengaluru

Date: September 30, 2024



Annexure I referred to in clause 1 of paragraph on the 'Report on Other Legal and Regulatory Requirements' of our report of even date

Re: Molbio Diagnostics Private Limited ('the Company')

In terms of the information and explanations sought by us and given by the Company and the books of account and records examined by us in the normal course of audit and to the best of our knowledge and belief, we state that:

- (i) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment, investment property and relevant details of right-of-use assets, except that the records for property, plant and equipment are maintained for group of similar assets and not for each individual asset.
- (B) The Company has maintained proper records showing full particulars of intangible assets.
- (b) Property, Plant and Equipment, investment property and right-of-use assets have not been physically verified by the management during the year. Hence, we are unable to comment on the discrepancies, if any.
- (c) The title deeds of all the immovable properties (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) are held in the name of the Company. Certain title deeds of the immovable properties, in the nature of freehold land & buildings are pledged with the banks and their title deeds are not available with the Company. The same has been independently confirmed by the bank.
- (d) The Company has not revalued its property, plant and equipment (including right of use assets) or intangible assets during the year ended March 31, 2024 and hence not commented upon.
- (e) As disclosed in Note 42(i) to the accompanying standalone Ind AS financial statements, there are no proceedings initiated or are pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.
- (ii) (a) Physical verification of inventory has been conducted at reasonable intervals during the year by management except for good-in-transit and inventories lying with third parties. In our opinion, the coverage and procedure of such verification by the management is appropriate. Inventories lying with third parties have been confirmed by such third parties to management as at March 31, 2024. There were no discrepancies of 10% or more noticed, in the aggregate for each class of inventory.
- (b) As disclosed in Note 16 to the accompanying standalone Ind AS financial statements, the Company has been sanctioned working capital limits in excess of Rs. five crores in aggregate from banks during the year on the basis of security of current assets of the Company. The Company does not have a process of preparing the financial statements on a quarterly basis. Accordingly, the quarterly statements filed by the Company with such banks cannot be reconciled with the audited/ reviewed books of accounts of the Company and hence we are unable to comment on the same.
- (iii) (a) During the year the Company has provided loans and stood guarantee as summarized below:

Particulars	Loans	Guarantees
Aggregate amount granted/ provided during the year		
- Subsidiary (Prognosys Medical Systems Private Limited)	₹ 130.00 Million	₹ 600.00 Million
- Subsidiary (Bigtec Private Limited)	₹ 417.50 Million	-
Balance outstanding as at balance sheet date (excluding interest accrued) in respect of above cases		
- Subsidiary (Prognosys Medical Systems Private Limited)	₹ 50.00 Million	₹ 600.00 Million
- Subsidiary (Bigtec Private Limited)	-	-

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

Other than the above, the Company has not provided loans, advances in the nature of loans, stood guarantee and provided security to the companies, firms, Limited Liability Partnerships or any other parties.

- (b) During the year the investments made, guarantees provided, security given and the terms and conditions of the grant of all loans and advances in the nature of loans, investments and guarantees to companies, firms, Limited Liability Partnerships or any other parties, as applicable, are not prejudicial to the Company's interest except that the Company has a provision for diminution in value of investment of ₹ 102.62 Million during the year ended March 31, 2024. These provisions have been prejudicial to the Company's interest.
- (c) The Company has granted loans during the year to subsidiary companies as stated in clause iii(a) above where the schedule of repayment of principal and payment of interest has been stipulated and the repayment or receipts are regular.
- (d) There are no amounts of loans and advances in the nature of loans granted to companies, firms, limited liability partnerships or any other parties which are overdue for more than ninety days.
- (e) The Company had granted loans to companies, which had fallen due during the year and the Company had renewed those existing loans during the year to the respective parties to settle the dues which had fallen due for the existing loans. The aggregate amount of such dues renewed and percentage of the aggregate to the total loans are as follows:

Name of Parties (A)	Aggregate amount of loans and advances in the nature of loans granted during the year (B)	Aggregate dues settled by renewal or extension or by fresh loans granted to same parties (C)	Percentage of the aggregate to the total loans or advances in the nature of loans granted during the year (D=C/B)
Prognosys Medical Systems Private Limited	₹ 130.00 Million	₹ 50.00 Million	38.46%
Bigtec Private Limited*	₹ 417.50 Million	₹ 539.99 Million	100.00%

* The Company had outstanding loan amounting to ₹ 122.49 Million as at March 31, 2023.

- (f) The Company has not granted any loans or advances in the nature of loans, either repayable on demand or without specifying any terms or period of repayment to companies, firms, Limited Liability Partnerships or any other parties. Accordingly, the requirement to report on clause 3(iii)(f) of the Order is not applicable to the Company and hence not commented upon.
- (iv) Loans, investments, guarantees and security in respect of which provisions of sections 185 and 186 of the Companies Act, 2013, as applicable, have been complied with by the Company.
- (v) The Company has neither accepted any deposits from the public nor accepted any amounts which are deemed to be deposits within the meaning of sections 73 to 76 of the Act and the rules made thereunder, to the extent applicable. Accordingly, the requirement to report on clause 3(v) of the Order is not applicable to the Company and hence not commented upon.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the rules made by the Central Government for the maintenance of cost records under section 148(1) of the Act related to the manufacture of the Company's products, and are of the opinion that prima facie, the specified accounts and records have been made and maintained. We have not, however, made a detailed examination of the same.
- (vii) (a) Undisputed statutory dues including goods and services tax, provident fund, employees' state insurance, income-tax, custom duty, cess and other material statutory dues, as applicable to the Company, have not been regularly deposited with the appropriate authorities and there have been a serious delays in large number of cases. According to the information and explanations given to us and based on audit procedures performed by us, no undisputed dues in respect of goods and services tax, professional tax,



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

provident fund, employees' state insurance, income-tax, service tax, sales-tax, duty of custom, duty of excise, value added tax, cess and other statutory dues which were outstanding, at the year end, for a period of more than six months from the date they became payable.

- (b) The dues of goods and services tax, provident fund, employees' state insurance, income-tax, sales-tax, service tax, custom duty, excise duty, value added tax, cess, and other statutory dues which have not been deposited on account of any dispute, are as follows:

Name of the Statute	Nature of the Dues	Amount of dispute (₹.)	Period to which the amount relates	Forum where it is pending
Income tax Act, 1961	Income tax	-*	FY 2017-18	Commissioner of Income Tax (Appeals)
CGST Act, 2017	Goods and service tax	₹ 115.43 Million	FY 2017-18 to FY 2020-21	Joint Commissioner of CGST
CGST Act, 2017	Goods and service tax	₹ 24.68 Million **	FY 2017-18 to FY 2020-21	Appellate Authority
Customs Act, 1962	Custom duty	₹ 0.70 Million	FY 2012-13	Commissioner of Customs (Appeals)
Customs Act, 1962	Custom duty	₹ 0.47 Million	FY 2017-18 to FY 2018-19	The Commissioner of Customs (Imports)
Central Sales Tax, 1944	Value added tax	₹ 0.45 Million	FY 2016-17	Appellate Authority

* Demand of ₹ Nil has been raised for FY 2017-18, however the brought forward loss has been disallowed which may impact tax liabilities for future years.

** Further, demands paid under protest amounting to ₹ 15.17 Million have not been adjusted in the above table.

Excludes additional interest and penalty, if any, at the time of final outcome of the appeals.

- (viii) As disclosed in Note 42(v) to the accompanying standalone Ind AS financial statements, the Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company and hence not commented upon.
- (ix) (a) The Company has defaulted in repayment of dues to financial institutions, banks and Government / debenture holders during the year as stated below. This matter has been disclosed in note 16 to the accompanying standalone Ind AS financial statements:

Nature of borrowing, including debt securities	Name of lender	Amount not paid on due date	Whether principal or interest	No. of days delay or unpaid	Remarks, if any
Vehicle Loans	HDFC Bank	₹ 0.03 Million	Principal and interest	15 days	1 installment

- (b) As disclosed in Note 42 (vi) to the accompanying standalone Ind AS financial statements, the Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.
- (c) Term loans obtained during the year were applied for the purpose for which the loans were obtained.
- (d) On an overall examination of the accompanying standalone Ind AS financial statements of the Company, the Company has used funds raised on short-term basis in the form of cash credit facility from banks aggregating to ₹ 234.66 Million for long-term purposes representing acquisition of property plant and equipment, investment property and repayment of loans.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

- (e) On an overall examination of the accompanying standalone Ind AS financial statements of the Company, the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries or associates. Further the Company does not have any joint ventures.
- (f) The Company has not raised loans during the year on the pledge of securities held in its subsidiaries or associate companies. Hence, the requirement to report on clause (ix)(f) of the Order is not applicable to the Company. Further the Company does not have any joint ventures.
- (x) (a) The Company has not raised any money during the year by way of initial public offer/ further public offer (including debt instruments) hence, the requirement to report on clause 3(x)(a) of the Order is not applicable to the Company and hence not commented upon.
- (b) The Company has not made any preferential allotment or private placement of shares /fully or partially or optionally convertible debentures during the year under audit and hence, the requirement to report on clause 3(x)(b) of the Order is not applicable to the Company and hence not commented upon.
- (xi) (a) According to the information and explanation given to us and based on the audit procedures performed by us, no fraud by the Company or no material fraud on the Company has been noticed or reported during the year. Further, as disclosed in note 43 to the accompanying standalone Ind AS financial statement, we have been informed that subsequent to the year-end, two frauds on the Company were noted, that were executed by external parties resulting in loss of ₹ 4.43 Million. The management has initiated necessary actions.
- (b) During the year, no report under sub-section (12) of section 143 of the Act has been filed by auditors, as applicable in Form ADT – 4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.
- (c) As represented to us by the management of the Company, there are no whistle blower complaints received by the Company during the year.
- (xii) The Company is not a Nidhi Company as per the provisions of the Act. Therefore, the requirement to report on clause 3(xii)(a) to 3(xii)(c) of the Order is not applicable to the Company and hence not commented upon.
- (xiii) Transactions with the related parties are in compliance with section 188 of the Act where applicable and the details have been disclosed in the notes to the accompanying standalone Ind AS financial statements, as required by the applicable accounting standards. The provisions of section 177 of the Act are not applicable to the Company and accordingly the reporting under clause 3(xiii) of the Order insofar as it relates to section 177 of the Act is not applicable to the Company and hence not commented upon.
- (xiv) (a) Though the Company is required to have an internal audit system under section 138 of the Act, it does not have the internal audit system commensurate with the size and nature of the business of the Company.
- (b) We were unable to obtain any of the internal audit reports of the Company, hence the internal audit reports have not been considered by us.
- (xv) The Company has not entered into any non-cash transactions with directors or persons connected with the directors as referred to in section 192 of the Act and hence requirement to report on clause 3(xv) of the Order is not applicable to the Company and hence not commented upon.
- (xvi) (a) The provisions of section 45-IA of the Reserve Bank of India Act, 1934 (2 of 1934) are not applicable to the Company. Accordingly, the requirement to report on clause (xvi)(a) of the Order is not applicable to the Company and hence not commented upon.
- (b) The Company is not engaged in any Non-Banking Financial or Housing Finance activities. Accordingly, the requirement to report on clause (xvi)(b) of the Order is not applicable to the Company and hence not commented upon.
- (c) The Company is not a Core Investment Company as defined in the regulations made by Reserve Bank of India. Accordingly, the requirement to report on clause 3(xvi)(c) of the Order is not applicable to the Company and hence not commented upon.



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

- (d) There is no Core Investment Company as a part of the Group, hence, the requirement to report on clause 3(xvi)(d) of the Order is not applicable to the Company and hence not commented upon.
- (xvii) The Company has not incurred cash losses in the current financial year or in the immediately preceding financial year.
- (xviii) There has been no resignation of the statutory auditors during the year and accordingly requirement to report on Clause 3(xviii) of the Order is not applicable to the Company and hence not commented upon.
- (xix) On the basis of the financial ratios disclosed in Note 40 to the accompanying standalone Ind AS financial statements, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the standalone Ind AS financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company, We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- (xx) (a) In respect of other than ongoing project, the Company has not transferred unspent amount to a fund specified in Schedule VII to the Act, within a period of six months from end of the financial year in compliance with second proviso to sub section (5) of section 135 of the Act as disclosed in Note 41 to the accompanying standalone Ind AS financial statements as follows:

Financial year	Amount unspent on corporate social responsibility activities for other than ongoing projects	Amount transferred to Fund specified in Schedule VII within six months end of the financial year	Amount transferred after due date
2021-22	₹ 32.49 Million	-	-
2022-23	₹ 52.04 Million	-	-

- (b) In respect of ongoing projects, the Company has not transferred unspent amount to a special account, within a period of thirty days from end of the financial year in compliance with section 135 (6) of the Companies Act as disclosed in Note 41 to the accompanying standalone Ind AS financial statements, stated as follows:

Financial year	Amount unspent on corporate social responsibility activities for ongoing projects	Amount transferred to Special Account within 30 days from the end of the financial year	Amount transferred after due date on August 26, 2024
2023-24	₹ 56.14 Million	-	₹ 56.14 Million

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI firm registration number: 101049W/E300004


per Sandeep Karnani
Partner

Membership Number: 061207

UDIN: 24061207BKBJYZ3401

Place of Signature: Bengaluru

Date: September 30, 2024



Annexure II to the Independent auditor's report of even date on the standalone Ind AS financial statements of Molbio Diagnostics Private Limited**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")**

We were engaged to audit the internal financial controls with reference to standalone Ind AS financial statements of Molbio Diagnostics Private Limited ("the Company") as of March 31, 2024, in conjunction with our audit of the standalone Ind AS financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") issued by the Institute of Chartered Accountants of India ("ICAI"). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to these standalone Ind AS financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing as specified under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both issued by ICAI.

Because of the matter described in Disclaimer of Opinion paragraph below, we were not able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on internal financial controls with reference to these standalone Ind AS financial statements of the Company.

Meaning of Internal Financial Controls With Reference to Standalone Ind AS Financial Statements

A company's internal financial control with reference to standalone Ind AS financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone Ind AS financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control with reference to standalone Ind AS financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone Ind AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the standalone Ind AS financial statements.

Disclaimer of Opinion

According to the information and explanation given to us, the Company has not established its internal financial control with reference to standalone Ind AS financial statements on criteria based on or considering the essential components of internal control stated in the Guidance Note issued by ICAI. Because of this reason, we are unable to obtain sufficient appropriate audit evidence to provide a basis for our opinion whether the Company had adequate internal financial controls with reference to standalone Ind AS financial statements as at March 31, 2024 and whether such internal financial controls were operating effectively. Accordingly, we do not express an opinion on Internal Financial Controls with reference to these standalone Ind AS financial statements.

Explanatory paragraph

We also have audited, in accordance with the Standards on Auditing issued by ICAI, as specified under Section 143(10) of the Act, the standalone Ind AS financial statements of Molbio Diagnostics Private Limited, which comprise the Balance Sheet as at March 31, 2024, and the related Statement of Profit and Loss, including the statement of Other Comprehensive Income, the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and notes to the standalone Ind AS financial statements, including a summary of material accounting policies and other explanatory information, and our report dated September 30, 2024 expressed an unqualified opinion. We have considered the disclaimer of opinion reported above in determining the nature, timing, and extent of audit tests applied in our audit of the standalone Ind AS financial statements of the Company, and the disclaimer does not affect our opinion on the standalone Ind AS financial statements of the Company.

For **S.R. Batliboi & Associates LLP**

Chartered Accountants

ICAI Firm Registration Number: 101049W/E3000004

per Sandeep Karnani

Partner

Membership Number: 061207

UDIN: 24061207BKBJYZ3401

Place of Signature: Bengaluru

Date: September 30, 2024



	Notes	(₹ in Million)	
		March 31, 2024	March 31, 2023
I Assets			
(1) Non-current assets			
(a) Property, plant and equipment	3	1,641.09	1,745.63
(b) Intangible assets	4	18.90	23.49
(c) Right-of-use assets	34	99.29	123.97
(d) Capital work-in-progress	3	15.83	-
(e) Investment property	5	329.69	-
(f) Financial assets			
(i) Investments	6	537.94	537.94
(ii) Other financial assets	7	167.23	274.75
(g) Deferred tax assets (net)	30	232.31	61.82
(h) Non-current tax assets (net)	9	130.56	289.81
(i) Other non-current assets	13	311.94	30.37
		3,484.78	3,087.78
(2) Current assets			
(a) Inventories	11	2,926.25	3,277.52
(b) Financial assets			
(i) Trade receivables	10	3,602.55	1,733.11
(ii) Cash and cash equivalents	12	182.62	43.14
(iii) Bank balances other than (ii) above	12	-	2.64
(iv) Loans	8	50.00	122.49
(v) Other financial assets	7	100.07	161.09
(c) Other current assets	13	425.72	767.59
		7,287.21	6,107.58
Total assets (1+2)		10,771.99	9,195.36
II Equity and liabilities			
(1) Equity			
(a) Equity share capital	14	22.54	22.54
(b) Other equity	15	8,477.30	7,367.20
Total equity		8,499.84	7,389.74
(2) Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	16	151.23	9.85
(ii) Lease liabilities	34	19.63	18.04
(b) Net employee defined benefit liabilities	17	3.21	1.78
		174.07	29.67
(3) Current liabilities			
(a) Financial liabilities			
(i) Borrowings	16	513.10	533.49
(ii) Lease liabilities	34	18.39	10.37
(iii) Trade payables			
(a) Total outstanding dues of micro enterprises and small enterprises	21	49.28	49.84
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	21	909.87	695.87
(iv) Other financial liabilities	19	96.09	103.98
(b) Net employee defined benefit liabilities	17	3.50	3.50
(c) Provisions	18	158.04	91.64
(d) Other current liabilities	20	349.81	287.26
		2,098.08	1,775.95
Total liabilities (2+3)		2,272.15	1,805.62
Total equity and liabilities (1+2+3)		10,771.99	9,195.36

Summary of material accounting policies

2.4

The accompanying notes are an integral part of the Standalone Ind AS Financial Statements.

As per our report of even date

For S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI firm registration number: 101049W/ E300004

per Sandeep Kamrani
Partner
Membership No: 061207
Place: Bengaluru
Date: September 30, 2024



For and on behalf of the Board of Directors of
Molbio Diagnostics Private Limited

Chandrasekhar Bhaskaran Nair
Director
DIN: 01787875
Place: Bengaluru
Date: September 30, 2024

Amol Narayan Lone
Chief Financial Officer

Place: Goa
Date: September 30, 2024

Sriram Natarajan
CEO & Director
DIN: 00013843
Place: Goa
Date: September 30, 2024

Darshan Karekar
Company Secretary
Membership number:
ACS A45125
Place: Goa
Date: September 30, 2024

		(₹ in Million)	
	Notes	For the year ended March 31, 2024	For the year ended March 31, 2023
I. Income			
Revenue from operations	22	7,563.15	3,265.72
Other income	23	65.22	81.01
Total income		7,628.37	3,346.73
II. Expenses			
Cost of raw material and components consumed	24	2,439.25	1,771.96
Changes in inventories of finished goods, work-in-progress and traded goods	25	217.56	(427.71)
Purchase of traded goods (refer note 36)		59.43	7.16
Employee benefit expenses	26	386.02	340.12
Depreciation and amortisation expenses	27	235.97	193.88
Finance costs	28	76.08	59.44
Other expenses	29(a)	2,423.96	1,173.33
Total expenses		5,838.27	3,118.18
III. Profit before tax and exceptional items (I - II)		1,790.10	228.55
IV. Exceptional items	29(b)	271.21	-
V. Profit before tax (III - IV)		1,518.89	228.55
VI. Tax expenses:			
(a) Current tax	30	574.15	69.54
(b) Deferred tax (credit) / charge	30	(170.17)	3.55
(c) Adjustment of tax relating to earlier years	30	3.85	-
Total tax expenses		407.83	73.09
VII. Profit for the year (V - VI)		1,111.06	155.46
VIII. Other comprehensive (loss) / income			
Other comprehensive (loss) / income not to be reclassified to profit or loss in subsequent periods:			
(i) Re-measurement (losses) / gains on defined benefit plan	33	(1.28)	1.94
Income tax effect on above	30	0.32	(0.49)
Total other comprehensive (loss) / income for the year (net of tax)		(0.96)	1.45
IX. Total comprehensive income / (loss) for the year (net of tax) (VII + VIII)		1,110.10	156.91
X. Earnings per equity share (EPS) (face value - ₹ 1 each)			
Basic (₹)	31	49.30	6.91
Diluted (₹)	31	49.27	6.90

Summary of material accounting policies

2.4

The accompanying notes are an integral part of the Standalone Ind AS Financial Statements.

As per our report of even date

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI firm registration number: 101049W/ E300004

per Sandeep Karnani

Partner

Membership No: 061207

Place: Bengaluru

Date: September 30, 2024



For and on behalf of the Board of Directors of

Molbio Diagnostics Private Limited

Chandrasekhar Bhaskaran Nair

Director

DIN: 01787875

Place: Bengaluru

Date: September 30, 2024

Amol Narayan Lone

Chief Financial Officer

Place: Goa

Date: September 30, 2024

Sriram Natarajan

CEO & Director

DIN: 00013843

Place: Goa

Date: September 30, 2024

Darshan Karekar

Company Secretary

Membership number:

ACS A45125

Place: Goa

Date: September 30, 2024

	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
A. Cash flow from / (used in) operating activities		
Profit before tax	1,518.89	228.55
Non cash adjustments to reconcile profit before tax to net cash flows:		
Depreciation and amortisation expenses	235.97	193.88
Provision for doubtful debts, advances and other receivables	309.26	0.91
Provision for inventories	168.59	-
Bad debts / advances written off	12.52	1.15
Impairment on investments (refer note 36)	102.62	0.15
Unrealised (gain) / loss on account of foreign exchange fluctuation (net)	(1.81)	7.37
Loss / (gain) on sale / discard of property, plant and equipment	1.14	(0.07)
Finance income	(44.55)	(65.09)
Finance costs	72.49	57.19
	2,375.12	424.04
Operating profit before working capital changes		
Working capital adjustments :		
Decrease / (increase) in inventories	182.68	(319.91)
(Increase) / decrease in trade receivables	(2,119.65)	669.88
Decrease / (increase) in non-current and current other financial and other assets	27.42	(192.41)
Increase in trade payables, non-current and current other financial, other liabilities and provisions	338.81	425.23
Cash generated from operations	804.38	1,006.83
Direct taxes paid (net of refund)	(427.02)	(327.87)
Net cash flow from operating activities (A)	377.36	678.96
B. Cash flow from / (used in) investing activities		
Purchase of property, plant and equipment (including capital work-in- progress and capital advances) and Intangible assets	(140.43)	(129.37)
Proceeds from sale of property, plant and equipment	-	0.25
Purchase of investment property	(329.69)	-
Interest income received	71.89	15.05
Investment / (redemption) in bank deposits (net)	113.95	(22.82)
Loans given to related parties	(547.50)	(523.04)
Loan repaid by the related parties	619.99	600.55
Investment in equity instruments of subsidiary	(102.62)	(144.60)
Investment in compulsorily convertible preference shares of subsidiary and associate	-	(306.11)
Net cash used in investing activities (B)	(314.41)	(510.09)
C. Cash flow from / (used in) financing activities		
Proceeds from issue of equity shares	-	400.01
Proceeds from termination of lease	31.17	-
Payment of interest portion of lease liabilities	(2.77)	(2.80)
Payment of principal portion of lease liabilities	(13.90)	(8.81)
Proceeds from long-term borrowings	269.11	14.56
Repayment of long-term borrowings	(41.14)	(15.25)
Proceeds / (repayment) from short-term borrowings (net)	(425.51)	(14.55)
Finance costs paid	(58.96)	(63.61)
Net cash (used in) / from financing activities (C)	(242.00)	309.55
Net increase in cash and cash equivalents (A+B+C)	(179.05)	478.42
Cash and cash equivalents at the beginning of the year	(46.52)	(524.94)
Cash and cash equivalents at the end of the year	(225.57)	(46.52)
Components of cash and cash equivalents		
Balances with banks		
- On current accounts	182.47	42.92
Cash on hand	0.15	0.22
Overdraft from bank	(408.19)	(89.66)
Total cash and cash equivalents	(225.57)	(46.52)
Non-cash investing activities		
Acquisition of right-of-use assets (refer note 34)	23.92	7.19



Handwritten signature



Handwritten signature

Explanatory notes to standalone Ind AS statements of cash flows

Particulars	(₹ in Million)	
	Changes in liabilities arising from financing activities	
	Borrowings (refer note 16)	Lease liabilities (including current portion of lease liabilities) (refer note 34)
As at April 01, 2023	453.68	28.41
Cash flow changes		
Proceeds from long-term borrowings	269.11	-
Repayment of long-term borrowings	(41.14)	-
Proceeds / (repayment) from short-term borrowings (net)	(425.51)	-
Payment of interest portion of lease liabilities	-	(2.77)
Payment of principal portion of lease liabilities	-	(13.90)
Non-cash changes		
Accretion of interest on lease liabilities (refer note 34)	-	2.77
Additions to lease liabilities	-	23.51
As at March 31, 2024	256.14	38.02
As at April 01, 2022	468.92	30.18
Cash flow changes		
Proceeds from long-term borrowings	14.56	-
Repayment of long-term borrowings	(15.25)	-
Proceeds / (repayment) from short-term borrowings (net)	(14.55)	-
Payment of interest portion of lease liabilities	-	(2.80)
Payment of principal portion of lease liabilities	-	(8.81)
Non-cash changes		
Accretion of interest on lease liabilities (refer note 34)	-	2.80
Additions to lease liabilities	-	7.04
As at March 31, 2023	453.68	28.41

Summary of material accounting policies

2.4

The accompanying notes are an integral part of the Standalone Ind AS Financial Statements.

As per our report of even date

For S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI firm registration number: 101049W/ E300004

For and on behalf of the Board of Directors of
Molbio Diagnostics Private Limited

per Sandeep Karnan
Partner
Membership No: 061207
Place: Bengaluru
Date: September 30, 2024



Chandrasekhar Bhaskaran Nair
Director
DIN: 01787875
Place: Bengaluru
Date: September 30, 2024

Amol Narayan Lone
Chief Financial Officer
Place: Goa
Date: September 30, 2024

Sriram Natarajan
CEO & Director
DIN: 00013843
Place: Goa
Date: September 30, 2024

Darshan Karekar
Company Secretary
Membership number:
ACS A45125
Place: Goa
Date: September 30, 2024



A. Equity share capital*

Equity shares of ₹ 10 each issued, subscribed and fully paid

As at April 01, 2022

Add: Issuance of share capital (refer note 14(f))

As at March 31, 2023

As at April 01, 2023

Add: Issuance of share capital

As at March 31, 2024

*Also refer note 14

Number (in Million)	₹ in Million
2.24	22.46
0.01	0.08
2.25	22.54
2.25	22.54
-	-
2.25	22.54

B. Other equity**

(₹ in Million)						
Particulars	Amount attributable to shareholders					Total other equity
	Reserves and surplus				Money received against share warrants	
	Retained earnings	Amalgamation reserve	Securities premium	Other reserves		
Balance as at April 01, 2022	5,016.58	92.78	1,548.75	148.75	3.50	6,810.36
Profit for the year	155.46	-	-	-	-	155.46
Other comprehensive income / (loss) for the year (net of taxes)***	1.45	-	-	-	-	1.45
Total comprehensive income	156.91	-	-	-	-	156.91
Issue of equity shares (refer note 14(f))	-	-	399.93	-	-	399.93
Balance as at March 31, 2023	5,173.49	92.78	1,948.68	148.75	3.50	7,367.20
Profit for the year	1,111.06	-	-	-	-	1,111.06
Other comprehensive (loss) / income for the year (net of taxes)***	(0.96)	-	-	-	-	(0.96)
Balance as at March 31, 2024	6,283.59	92.78	1,948.68	148.75	3.50	8,477.30

**Also refer note 15

***As required under Ind AS compliant Schedule III, the Company has recognised remeasurement (losses) / gains of defined benefit plans as part of retained earnings.

Summary of material accounting policies

24

The accompanying notes are an integral part of the Standalone Ind AS Financial Statements

As per our report of even date

For S R. Batliboi & Associates LLP
Chartered Accountants
ICAI firm registration number: 101049W/ E300004

per Sandeep Kamani
Partner
Membership No. 061207
Place: Bengaluru
Date: September 30, 2024



For and on behalf of the Board of Directors of
Molbio Diagnostics Private Limited

Chandrasekhar Bhaskaran Nair
Director
DIN: 01787875
Place: Bengaluru
Date: September 30, 2024

Amol Natarajan Lone
Chief Financial Officer

Place: Goa
Date: September 30, 2024

Sriram Natarajan
CEO & Director
DIN: 00013843
Place: Goa
Date: September 30, 2024

Darshan Karekar
Company Secretary
Membership number:
ACS A45125
Place: Goa
Date: September 30, 2024

(This space has been intentionally left blank)

1. Corporate Information

The Standalone Financial Statements comprise financial statements of Molbio Diagnostics Private Limited ('the Company') (CIN U33125GA2000PTC002909) for the year ended March 31, 2024. The Company is a private company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. The registered office of the Company is located at Plot No.L-46, Phase II-D Verna Industrial Area, Verna, Salcete South Goa, Goa – 403722. The Company is engaged in the business of manufacturing chip based diagnostic devices, chips and reagents.

The Standalone Ind AS Financial Statements were approved by the Board of Directors and authorised for issue in accordance with a resolution of the directors on September 30, 2024.

2. Material accounting policies

The material accounting policies applied by the Company in the preparation of its Standalone Ind AS Financial Statements are listed below. Such accounting policies have been applied consistently to all the periods presented in these financial statements, unless otherwise indicated.

2.1. Basis of preparation

The Standalone Ind AS financial statements of the Company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended from time to time) and presentation requirements of Division II of Schedule III to the Companies Act, 2013, (Ind AS compliant Schedule III), as applicable to the Ind AS Financial Statement.

The Standalone Ind AS Financial Statements have been prepared by the Company as a going concern on the basis of relevant Ind AS that are effective as at March 31, 2024.

The Standalone Ind AS Financial Statements have been prepared on a historical cost basis, except for certain financial assets and liabilities, plan assets of defined benefit obligation, (refer accounting policy regarding financial instruments) which have been measured at fair value.

The functional and presentation currency of the Company is Indian Rupee ('₹') which is the currency of the primary economic environment in which the Company operates. All values are rounded to the nearest million with two decimals ('₹ ,000,000.00'), except when otherwise indicated.

2.2 New and amended standards (Ind AS)

The following amended standards as considered applicable were effective during the year, however, these amendments had no material impact on the financial statements of the Company.

(i) Definition of Accounting Estimates - Amendments to Ind AS 8

The amendments clarify the distinction between changes in accounting estimates and changes in accounting policies and the correction of errors. It has also been clarified how entities use measurement techniques and inputs to develop accounting estimates. The amendments are effective for annual reporting periods beginning on or after April 01, 2023 and apply to changes in accounting policies and changes in accounting estimates that occur on or after the start of that period.

The amendments does not have a material impact on the Company's Standalone Ind AS Financial Statements.

(ii) Disclosure of Accounting Policies - Amendments to Ind AS 1

The amendments aim to help entities provide accounting policy disclosures that are more useful by replacing the requirement for entities to disclose their 'significant' accounting policies with a requirement to disclose their 'material' accounting policies and adding guidance on how entities apply the concept of materiality in making decisions about accounting policy disclosures. The amendments to Ind AS 1 are applicable for annual periods beginning on or after April 01, 2023. Consequential amendments have been made in Ind AS 107.

The amendment does not have a material impact on the Standalone Ind AS Financial Statements of the Company.

(iii) Deferred Tax related to Assets and Liabilities arising from a Single Transaction - Amendments to Ind AS 12

The amendments narrow the scope of the initial recognition exception under Ind AS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments should be applied to transactions that occur on or after the beginning of the earliest comparative period presented. In addition, at the beginning of



the earliest comparative period presented, a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability should also be recognised for all deductible and taxable temporary differences associated with leases and decommissioning obligations. Consequential amendments have been made in Ind AS 101. The amendments to Ind AS 12 are applicable for annual periods beginning on or after April 01, 2023.

The amendment does not have a material impact on the Company's Standalone Ind AS Financial Statements.

2.3 Recent Indian Accounting Standards (Ind AS)

There are no standards that are notified and not yet effective as on the date.

2.4 Summary of material accounting policies:

a. Current versus non-current classification

The Company presents assets and liabilities in the Standalone Ind AS Balance Sheet based on current/ non-current classification. An asset is treated as current when it is:

- Expected to be realised or intended to be sold or consumed in normal operating cycle
- Held primarily for the purpose of trading
- Expected to be realised within twelve months after the reporting period; or
- Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

- It is expected to be settled in normal operating cycle
- It is held primarily for the purpose of trading
- It is due to be settled within twelve months after the reporting period; or
- There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

All other liabilities are classified as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities.

Advance tax paid is classified as non-current assets.

The operating cycle is the time between the acquisition of assets for processing and their realisation in cash and cash equivalents.

b. Fair value measurement

The Company measures financial instruments at fair value at each Balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability.

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the Standalone Ind AS Financial Statements are categorised within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

- Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities



Handwritten signature/initials.



Handwritten signature/initials.

- Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable
- Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable

For assets and liabilities that are recognised in the Standalone Ind AS Financial Statements on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorisation (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period.

For the purpose of fair value disclosures, the Company has determined classes of assets and liabilities on the basis of the nature, characteristics and risks of the asset or liability and the level of the fair value hierarchy as explained above.

This note summarises accounting policy for fair value. Other fair value related disclosures are given in the relevant notes.

- ▶ Disclosures for valuation methods, significant estimates and assumptions
- ▶ Quantitative disclosures of fair value measurement hierarchy (refer note 38)
- ▶ Financial instruments (including those carried at amortised cost)

c. Revenue recognition

Revenue from operations is recognised when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The Company has generally concluded that it is the principal in its revenue arrangements because it typically controls the goods or services before transferring them to the customer.

Revenue is recognised when the Company satisfies a performance obligation by transferring a promised good or service to the customer, which is when the customer obtains control of the good or service. A performance obligation may be satisfied at a point in time or over time. The amount of revenue recognised is the amount allocated to the satisfied performance obligation.

The specific recognition criteria described below must be met before revenue is recognised:

Revenue from contracts with customers

(i) Revenue from sale of goods:

Revenue from sale of goods is recognised at the point in time when control of the asset is transferred to the customer, generally on delivery of the goods. Revenue from the sale of goods is measured at the fair value of the consideration received or receivable, net of returns and allowances, trade discounts and volume rebates.

(ii) Other operating revenue:

Revenues from maintenance contracts

Revenues from maintenance contracts are recognised pro-rata over the period of the contract as and when services are rendered.

Installation services

The Company provides installation services that are together with the sale of equipment to a customer. The installation services do not significantly customise or modify the equipment.

Contracts for bundled sales of equipment and installation services are comprised of two performance obligations because the equipment and installation services are both sold on a stand-alone basis and are distinct within the context of contract. Accordingly, the Company allocates the transaction price based on the relative stand-alone selling prices of the equipment and installation services.

The Company recognises revenue from installation services at a point in time because the customer receives and consumes the benefits provided to them only after installation.

Other income

(i) Interest Income

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the applicable interest rate.



For all financial instruments measured either at amortised cost or at fair value through other comprehensive income, interest income is recorded using the effective interest rate (EIR). EIR is the rate that exactly discounts the estimated future cash payments or receipts over the expected life of the financial instrument or a shorter period, where appropriate, to the gross carrying amount of the financial asset or to the amortised cost of a financial liability. When calculating the effective interest rate, the Company estimates the expected cash flows by considering all the contractual terms of the financial instrument but does not consider the expected credit losses. Interest income is included in finance income in the statement of profit and loss.

(ii) Export benefits

Export incentives receivables are accrued for, when the right to receive the credit is established and there is no significant uncertainty regarding the realisability of the incentive

Cost to obtain a contract

The Company pays sales commission to its vendors for the contracts that they obtain for sales of chip based diagnostic devices, chips and reagents. The Company applies the optional practical expedient to immediately expense costs to obtain a contract if the amortisation period of the asset that would have been recognised is one year or less. As such, sales commission are immediately recognised as an expense and included as a part of other expenses.

Contract balances

(i) Contract assets

A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If the Company performs by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognised for the earned consideration that is conditional. Contract assets are transferred to receivables when the rights become unconditional and contract liabilities are recognised as and when the performance obligation is satisfied.

Contract assets are subject to impairment assessment. Refer to accounting policies of financial assets in section (j) Financial assets - Impairment of financial assets and section (m) Financial instruments below.

The Company has used the practical expedient provided in Ind AS 115.121 to not disclose the amount of remaining performance obligations for contracts in which the right to consideration from a customer corresponds directly with the performance obligation completed till date.

(ii) Trade receivables

A receivable is recognised if an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). Refer to accounting policies of financial assets in section (j) Financial assets - Impairment of financial assets and section (m) Financial instruments below.

(iii) Contract liabilities

A contract liability is recognised if a payment is received, or a payment is due (whichever is earlier) from a customer before the Company transfers the related goods or services. Contract liabilities are recognised as revenue when the Company performs under the contract (i.e., transfers control of the related goods or services to the customer).

d. Taxes on income


Current income tax

Tax expense for the year comprises current and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the Standalone Ind AS statement of Profit and Loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The Company's liability for current tax is calculated using the tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

Current income tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income ('OCI') or in equity). Current tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and considers whether it is probable that a taxation authority will accept an uncertain tax treatment. The Company shall reflect the effect of uncertainty for each uncertain tax treatment by using either most likely method or expected value method, depending on which method predicts better resolution of the treatment.



Handwritten signature.



Handwritten signature.

Deferred tax

Deferred tax is the tax expected to be payable or recoverable on differences between the carrying values of assets and liabilities in the Standalone Ind AS Financial Statements and the corresponding tax bases used in the computation of the taxable profit and is accounted for using the liability model. Deferred tax liabilities are generally recognised for all the taxable temporary differences. In contrast, deferred tax assets are only recognised to the extent that it is probable that future taxable profits will be available against which the temporary differences can be utilised.

Deferred tax assets are recognised for all deductible temporary differences, carry forward of unused tax credits and unused tax losses, to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the balance sheet date.

Deferred tax relating to items recognised outside profit or loss is recognised outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

e. Property, plant and equipment

Property, plant and equipment are stated at cost, net of accumulated depreciation and accumulated impairment losses, if any. Such cost includes the cost of replacing part of the property, plant and equipment and borrowing costs for long-term construction projects if the recognition criteria are met. When significant parts of property, plant and equipment are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. All other repair and maintenance costs are recognised in profit or loss as incurred.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate assets are derecognised when replaced. All other repairs and maintenance are charged to profit and loss during the reporting period in which they are incurred.

The Company identifies and determines cost of each component/ part of the asset separately, if the component/ part has a cost which is significant to the total cost of the asset having useful life that is materially different from that of the remaining asset. These components are depreciated over their useful lives; the remaining asset is depreciated over the life of the principal asset.

Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows:

Sl. No.	Block	Useful lives estimated by the management (in years)
1	Building – factory on leasehold land	30
2	Plant and machinery	5-15
3	Furnitures and fixtures	10
4	Office equipments	5
5	Electrical installations & fittings	10
6	Computer equipments	3
7	Vehicles	8

Leasehold improvements are depreciated over the period of lease or estimated useful life, whichever is lower, on straight-line basis.

The management believes that these estimated useful lives are realistic and reflect fair approximation of the period over which the assets are likely to be used.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.



Handwritten signature



An item of property, plant and equipment and any significant part initially recognised is derecognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss when the asset is derecognised.

The Company, based on management estimate, depreciates certain items of building, plant and equipment over estimated useful lives which are different from the useful life prescribed in Schedule II to the Companies Act, 2013.

f. Investment properties

Investment properties are measured initially at cost, including transaction costs. Subsequent to initial recognition, investment properties are stated at cost less accumulated depreciation and accumulated impairment loss, if any.

The cost includes the cost of replacing parts and borrowing costs for long-term construction projects if the recognition criteria are met. When significant parts of the investment properties are required to be replaced at intervals, the Company depreciates them separately based on their specific useful lives. All other repair and maintenance costs are recognised in profit or loss as incurred.

Though the Company measures investment properties using cost-based measurement, the fair value of investment properties are disclosed in the notes. Fair values are determined based on an annual evaluation performed by an accredited external independent valuer applying a valuation model recommended by the International Valuation Standards Committee.

Investment properties are derecognised either when they have been disposed of or when they are permanently withdrawn from use and no future economic benefit is expected from their disposal. The difference between the net disposal proceeds and the carrying amount of the asset is recognised in profit or loss in the period of derecognition. In determining the amount of consideration from the derecognition of investment properties the Company considers the effects of variable consideration, existence of a significant financing component, non-cash consideration, and consideration payable to the buyer (if any).

Transfers are made to (or from) investment properties only when there is a change in use. Transfers between investment property, owner-occupied property and inventories do not change the carrying amount of the property transferred and they do not change the cost of that property for measurement or disclosure purposes.

g. Intangible assets

Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortisation and accumulated impairment losses. Internally generated intangibles, excluding capitalised development costs, are not capitalised and the related expenditure is reflected in profit or loss in the period in which the expenditure is incurred.

Computer software is amortised over the useful life of 3 years on straight-line basis.

Intangible assets with finite lives are amortised over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortisation period and the amortisation method for an intangible asset with a finite useful life are reviewed at least at the end of each reporting period with the effect of any change in the estimate being accounted for on a prospective basis. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset are considered to modify the amortisation period or method, as appropriate, and are treated as changes in accounting estimates. The amortisation expense on intangible assets with finite lives is recognised in the statement of profit and loss unless such expenditure forms part of carrying value of another asset.

An intangible asset is derecognised upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of profit and loss, when the asset is derecognised.

h. Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalised as part of the cost of the asset until such time as the assets are substantially ready for the intended use or sale. All other borrowing costs are expensed in the period in which they occur. Borrowing costs consist of interest and other costs that an entity incurs in connection with the borrowing of funds. Borrowing cost also includes exchange differences to the extent regarded as an adjustment to the borrowing costs.

i. Leases

The Company has lease contracts for office spaces. The Company assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration.



Company as a lessee

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognises lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

Right-of-use assets

The Company recognises right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and accumulated impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognised, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Right-of-use assets are depreciated on a straight-line basis over the shorter of the lease term and the estimated useful lives of the assets.

If ownership of the leased asset transfers to the Company at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

The right-of-use assets are also subject to impairment. Refer to the accounting policies stated under 'Impairment of non-financial assets'.

Lease liabilities

At the commencement date of the lease, the Company recognises lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate. Variable lease payments that do not depend on an index or a rate are recognised as expenses (unless they are incurred to produce inventories) in the period in which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Company uses its incremental borrowing rate at the lease commencement date because the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the lease payments (e.g., changes to future payments resulting from a change in an index or rate used to determine such lease payments) or a change in the assessment of an option to purchase the underlying asset.

Short term leases and leases of low-value assets

The Company applies the short-term lease recognition exemption to its short-term leases (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered to be low value. Lease payments on short-term leases and leases of low-value assets are recognised as expense on a straight-line basis over the lease term.

j. Impairment of non-financial assets

As at the end of each accounting year, the Company reviews the carrying amounts of its PPE and intangible assets determine whether there is any indication that those assets have suffered an impairment loss. If such indication exists, the said assets are tested for impairment so as to determine the impairment loss, if any. Intangible assets with indefinite life are tested for impairment each year.

Impairment loss is recognised when the carrying amount of an asset exceeds its recoverable amount. Recoverable amount is determined:

- (i) in the case of an individual asset, at the higher of the fair value less costs of disposal and the value in use; and
- (ii) in the case of a cash generating unit (a group of assets that generates identified, independent cash flows), at the higher of the cash generating unit's net fair value less costs of disposal and the value in use.


The amount of value in use is determined as the present value of estimated future cash flows from the continuing use of an asset and from its disposal at the end of its useful life. For this purpose, the discount rate (pre-tax) is determined based on the weighted average cost of capital of the company suitably adjusted for risks specified to the estimated cash flows of the asset.

For this purpose, a cash generating unit is ascertained as the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

If recoverable amount of an asset (or cash generating unit) is estimated to be less than its carrying amount, such deficit is recognised immediately in the statement of profit and loss as impairment loss and the carrying amount of the asset (or cash generating unit) is reduced to its recoverable amount.



Handwritten signature



In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. In determining fair value less costs of disposal, recent market transactions are taken into account. If no such transactions can be identified, an appropriate valuation model is used. These calculations are corroborated by valuation multiples other available fair value indicators.

The Company bases its impairment calculation on detailed budgets and forecast calculations, which are prepared separately for each of the Company's CGUs to which the individual assets are allocated. To estimate cash flow projections beyond periods covered by the most recent budgets/forecasts, the Company extrapolates cash flow projections in the budget using a steady or declining growth rate for subsequent years, unless an increasing rate can be justified. In any case, this growth rate does not exceed the long-term average growth rate for the products, industries, or country in which the Company operates, or for the market in which the asset is used.

Impairment losses are recognised in the statement of profit and loss.

When an impairment loss subsequently reversed, the carrying amount of the asset (or cash generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss is recognised for the asset (or cash generating unit) in prior years. A reversal of an impairment loss is recognised immediately in the statement of profit and loss.

k. Provisions and contingent liabilities

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement is recognised as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit and loss net of any reimbursement.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

If the Company has a contract that is onerous, the present obligation under the contract is recognised and measured as a provision. However, before a separate provision for an onerous contract is established, the Company recognises any impairment loss that has occurred on assets dedicated to that contract.

An onerous contract is a contract under which the unavoidable costs (i.e., the costs that the Company cannot avoid because it has the contract) of meeting the obligations under the contract exceed the economic benefits expected to be received under it. The unavoidable costs under a contract reflect the least net cost of exiting from the contract, which is the lower of the cost of fulfilling it and any compensation or penalties arising from failure to fulfil it. The cost of fulfilling a contract comprises the costs that relate directly to the contract (i.e., both incremental costs and an allocation of costs directly related to contract activities).

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognised because it cannot be measured reliably. The Company does not recognise a contingent liability but discloses its existence in the Standalone Ind AS Financial Statements.

Provisions and contingent liability are reviewed at each balance sheet.

Warranty provisions

The Company provides warranties for its products, systems and services, undertaking to repair or replace the items that fail to perform satisfactorily during the warranty period. Provision represents the amount of the expected cost based on technical evaluation and past experience of meeting such obligations. It is expected that this expenditure will be incurred over the contractual warranty period.

l. Retirement and other employee benefits

Retirement benefit in the form of provident fund and pension fund are defined contribution scheme. The Company has no obligation, other than the contribution payable. The Company recognises contribution payable to provident fund and pension fund as expenditure, when an employee renders the related service. If the contribution payable to the scheme for service received before the balance sheet date exceeds the contribution already paid, the deficit payable to the scheme is recognised as a liability after deducting the contribution already paid. If the contribution already paid exceeds the contribution due for services received before the balance sheet date, then excess is recognised as an asset to the extent that the pre-payment will lead to, for example, a reduction in future payment or a cash refund.



6



Accumulated leave, which is expected to be utilized within the next twelve months, is treated as short-term employee benefit. The Company measures the expected cost of such absences as the additional amount that it expects to pay as a result of the unused entitlement that has accumulated at the reporting date. The Company recognises expected cost of short-term employee benefit as an expense, when an employee renders the related service.

The Company treats accumulated leave expected to be carried forward beyond twelve months, as long-term employee benefit for measurement purposes. Such long-term compensated absences are provided for based on the actuarial valuation using the projected unit credit method at the reporting date. Actuarial gains/losses are immediately taken to the statement of profit and loss and are not deferred. The obligations are presented as current liabilities in the Standalone Ind AS Balance Sheet if the entity does not have an unconditional right to defer the settlement for at least twelve months after the reporting date. The Company presents the leave as a current liability in the Standalone Ind AS Balance Sheet, to the extent it does not have an unconditional right to defer its settlement for twelve months after the reporting date.

The cost of providing benefits under the defined benefit plan is determined using the projected unit credit method using actuarial valuation to be carried out at each balance sheet date.

Re-measurements, comprising of actuarial gains and losses, the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability and the return on plan assets (excluding amounts included in net interest on the net defined benefit liability), are recognised immediately in the Standalone Ind AS Balance Sheet with a corresponding debit or credit to retained earnings through OCI in the period in which they occur. Re-measurements are not reclassified to profit or loss in subsequent periods.

Past service costs are recognised in profit or loss on the earlier of:

- a) The date of the plan amendment or curtailment, and
- b) The date that the Company recognises related restructuring costs

Net interest is calculated by applying the discount rate to the net defined benefit liability or asset. The Company recognises the following changes in the net defined benefit obligation as an expense in the statement of profit and loss:

- a) Service costs comprising current service costs, past-service costs, gains and losses on curtailments and non-routine settlements; and
- b) Net interest expense or income.

m. Financial instruments

Initial recognition and measurement of financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contract embodying the related financial instruments. All financial assets, financial liabilities contracts are initially measured at transaction cost and where such values are different from the fair value, at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit and loss) are added to or deducted from the fair value measured on initial recognition of financial asset or financial liability. Transaction costs directly attributable to the acquisition of financial assets and financial liabilities at fair value through profit and loss are immediately recognised in the statement of profit and loss.

Financial assets are classified, at initial recognition, as subsequently measured at amortised cost, fair value through profit or loss and fair value through other comprehensive income. The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. With the exception of trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient, the Company initially measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss, transaction costs. Trade receivables that do not contain a significant financing component or for which the Company has applied the practical expedient are measured at the transaction price as disclosed under Revenue recognition policy.

In order for a financial asset to be classified and measured at amortised cost, it needs to give rise to cash flows that are 'solely payments of principal and interest (SPPI)' on the principal amount outstanding. This assessment is referred to as the SPPI test and is performed at an instrument level. Financial assets with cash flows that are not SPPI are classified and measured at fair value through profit or loss, irrespective of the business model.

Financial liabilities are classified, at initial recognition, as financial liabilities at fair value through profit or loss, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate.

All financial liabilities are recognised initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts.



Subsequent measurement of financial instruments

For purposes of subsequent measurement:

- a. Financial assets are classified in below categories:
 - Financial assets at amortised cost
 - Financial assets at fair value through other comprehensive income – Debt instruments
 - Financial assets at fair value through other comprehensive income – Equity instruments
 - Financial assets at fair value through profit or loss (FVTPL)
- b. Financial liabilities are classified in two categories:
 - Financial liabilities at fair value through profit or loss
 - Financial liabilities at amortised cost (loans and borrowings)

Effective interest method

The effective interest method is a method of calculating the amortised cost of a financial instrument and of allocating interest income or expense over the relevant period. The effective interest rate is the rate that exactly discounts future cash receipts or payments through the expected life of the financial instrument, or where appropriate, a shorter period.

Financial assets

a. Financial assets at amortised cost

Financial assets are measured at amortised cost if these financial assets are held within a business model whose objective is to hold these assets in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

b. Financial assets measured at fair value

Financial assets are measured at fair value through other comprehensive income if these financial assets are held within a business model whose objective is to hold these assets in order to collect contractual cash flows and to sell these financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial asset not measured at amortised cost or at fair value through other comprehensive income is carried at fair value through the statement of profit and loss.

For financial assets maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

c. Equity investments

Upon initial recognition, the Company can elect to classify irrevocably its equity investments as equity instruments designated at fair value through OCI when they meet the definition of equity under Ind AS 32 Financial Instruments: Presentation and are not held for trading. The classification is determined on an instrument-by-instrument basis. Equity instruments which are held for trading and contingent consideration recognised by an acquirer in a business combination to which Ind AS103 applies are classified as at FVTPL.

Gains and losses on these financial assets are never recycled to profit or loss. Dividends are recognised as other income in the statement of profit and loss when the right of payment has been established, except when the Company benefits from such proceeds as a recovery of part of the cost of the financial asset, in which case, such gains are recorded in OCI. Equity instruments designated at fair value through OCI are not subject to impairment assessment.

The Company elected to classify irrevocably its equity investments in the entities other than subsidiaries.

Equity investments in subsidiaries are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in subsidiaries, the difference between net disposal proceeds and the carrying amounts are recognised in the statement of profit and loss.

Investment in preference shares of the subsidiary and associate companies are treated as equity instruments if the same are convertible into equity shares or are redeemable out of the proceeds of equity instruments issued for the purpose of redemption of such investments. Investment in preference shares not meeting the aforesaid conditions are classified as debt instruments at FVTPL.



Handwritten signature in blue ink.



d. Impairment of financial assets

The Company recognises an allowance for expected credit losses (ECLs) for all debt instruments not held at fair value through profit or loss. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive, discounted at an approximation of the original effective interest rate. The expected cash flows will include cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECLs are recognised in two stages. For credit exposures for which there has not been a significant increase in credit risk since initial recognition, ECLs are provided for credit losses that result from default events that are possible within the next 12-months (a 12-month ECL). For those credit exposures for which there has been a significant increase in credit risk since initial recognition, a loss allowance is required for credit losses expected over the remaining life of the exposure, irrespective of the timing of the default (a lifetime ECL).

For trade receivables and contract assets, the Company applies a simplified approach in calculating ECLs. Therefore, the Company does not track changes in credit risk, but instead recognises a loss allowance based on lifetime ECLs at each reporting date. The Company has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

For financial assets maturing within one year from the balance sheet date, the carrying amounts approximates fair value due to the short maturity of these instruments.

e. De-recognition of financial assets

The Company de-recognises a financial asset only when the contractual rights to the cash flows from the financial asset expire, or it transfers the financial asset and the transfer qualifies for de-recognition under Ind AS 109.

If the Company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Company recognises its retained interest in the assets and an associated liability for amounts it may have to pay.

If the Company retains substantially all the risks and rewards of ownership of a transferred financial asset, the Company continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

On de-recognition of a financial asset in its entirety, the difference between the carrying amount measured at the date of de-recognition and the consideration received is recognised in statement of profit or loss.

Financial liabilities and equity instruments

a. Classification as debt or equity

Financial liabilities and equity instruments issued by the Company are classified according to the substance of the contractual arrangements entered into and the definitions of a financial liability and an equity instrument.

b. Equity Instruments

An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities. Equity instruments are recorded at the proceeds received, net of direct issue costs.

c. Financial Liabilities at amortised cost

Financial liabilities are initially measured at fair value, net of transaction costs, and are subsequently measured at amortised cost, using the effective interest rate method where the time value of money is significant. Interest bearing bank loans, overdrafts and issued debt are initially measured at fair value and are subsequently measured at amortised cost using the effective interest rate method. Any difference between the proceeds (net of transaction costs) and the settlement or redemption of borrowings is recognised over the term of the borrowings in the statement of profit and loss.

For trade and other payables maturing within one year from the balance sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

d. Financial liabilities at fair value through profit or loss

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss.



Handwritten signature in blue ink.



e. De-recognition of financial liabilities

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

f. Financial guarantee contracts

Financial guarantee contracts issued by the Company are those contracts that require a payment to be made to reimburse the holder for a loss it incurs because the specified debtor fails to make a payment when due in accordance with the terms of a debt instrument. Financial guarantee contracts are recognised initially as a liability at fair value, adjusted for transaction costs that are directly attributable to the issuance of the guarantee. Subsequently, the liability is measured at the higher of the amount of loss allowance determined as per impairment requirements of Ind AS 109 and the amount recognised less, when appropriate, the cumulative amount of income recognised in accordance with the principles of Ind AS 115.

Off-setting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the Standalone Ind AS Balance Sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

n. Inventories

Inventories are measured at the lower of cost and net realisable value. The cost of inventories is based on the weighted average formula, and includes expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their present location and condition. In the case of manufactured inventories and work-in-progress, cost includes an appropriate share of fixed production overheads based on normal operating capacity.

Provisions are made towards slow-moving and obsolete items based on historical experience of utilisation on a product category basis, which consideration of product lines and market conditions.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. The net realisable value of work-in-progress is determined with reference to the selling prices of related finished products.

Raw materials, components and other supplies held for use in the production of finished products are not written down below cost except in cases where material prices have declined and it is estimated that the cost of the finished products will exceed their net realisable value.

The comparison of cost and net realisable value is made on an item-by-item basis.

o. Segment reporting

Operating segments are identified as those components of the Company (a) that engage in business activities to earn revenues and incur expenses (including transactions with any of the Company's other components); (b) whose operating results are regularly reviewed by the Company's Chief Operating Decision Maker (CODM) to make decisions about resource allocation and performance assessment and (c) for which discrete financial information is available. The accounting policies consistently used in the preparation of Standalone Ind AS Financial Statements are also applied to record revenue and expenditure in individual segments. The Company is engaged in the business of manufacturing chip based diagnostic devices, chips and reagents. Accordingly, the Company's activities and business is reviewed regularly by the chief operating decision maker from an overall business perspective, rather than reviewing its products/services as individual standalone components and therefore subject to the same risk and reward and accordingly falls within single business segment.

p. Cash and cash equivalents

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less that are readily convertible to a known amount of cash and which are subject to an insignificant risk of changes in value.

For the purpose of the statement of cash flows, cash and cash equivalents consist of cash and short-term deposits, as defined above, as they are considered an integral part of the Company's cash management.



Handwritten signature in blue ink.



q. Foreign currencies

The Standalone Ind AS Financial Statements are presented in INR, which is also the Company's functional currency.

Transactions in foreign currencies are initially recorded at functional currency spot rates at the date the transaction first qualifies for recognition. However, for practical reasons, the Company uses average rate if the average approximates the actual rate at the date of the transaction.

Monetary assets and liabilities denominated in foreign currencies are translated at the functional currency spot rates of exchange at the reporting date.

Exchange differences arising on settlement or translation of monetary items are recognised in profit or loss.

Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates at the dates of the initial transactions. Non-monetary items measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value is determined. The gain or loss arising on translation of non-monetary items measured at fair value is treated in line with the recognition of the gain or loss on the change in fair value of the item (i.e., translation differences on items whose fair value gain or loss is recognised in OCI or profit or loss are also recognised in OCI or profit or loss, respectively).

Exchange differences arising on the retranslation or settlement of other monetary items are included in the statement of profit and loss for the period.

r. Corporate social responsibility ('CSR') expenditure

The Company charges its CSR expenditure during the year to the statement of profit and loss. Refer note 41 for details.

s. Earnings per share

The Company presents basic and diluted Earnings per share for its ordinary shares. Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. Partly paid equity shares are treated as a fraction of an equity share to the extent that they are entitled to participate in dividends relative to a fully paid equity share during the reporting period. The weighted average number of equity shares outstanding during the period is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all potential dilutive equity shares.

t. Exceptional Items

Exceptional Items represents the nature of transactions which are not in recurring nature during the ordinary course of business and are of such size, nature or incidence that their separate disclosure is considered necessary to explain the performance of the Company and lead to increase/ decrease in profit/ loss for the year.

u. Climate – related matters

The Company considers climate-related matters in estimates and assumptions, where appropriate. This assessment includes a wide range of possible impacts on the Company due to both physical and transition risks. Even though the Company believes its business model and products will still be viable after the transition to a low-carbon economy, climate-related matters increase the uncertainty in estimates and assumptions underpinning several items in the standalone Ind AS financial statements. Even though climate-related risks might not currently have a significant impact on measurement, the Company is closely monitoring relevant changes and developments, such as new climate-related legislation.



Handwritten signature in blue ink.



3 Property, plant and equipment and capital work-in-progress

Particulars	Property, plant and equipment								Capital work-in-progress ('CWIP')
	Building - factory on leasehold land	Plant and machinery	Furnitures and fixtures	Office equipments	Electrical installations & fittings	Computer equipments	Vehicles	Total	
Gross Block (at cost / deemed cost)									
As at April 01, 2022	591.63	1,508.57	68.37	6.99	84.58	13.74	59.55	2,333.43	-
Additions	2.14	72.71	5.45	-	3.97	4.82	15.06	104.15	104.15
Disposals/ transfers	-	-	-	-	-	-	(0.49)	(0.49)	(104.15)
As at March 31, 2023	593.77	1,581.28	73.82	6.99	88.55	18.56	74.12	2,437.09	-
Additions	1.71	87.17	1.38	0.70	0.39	6.47	6.94	104.76	120.59
Disposals/ transfers	(0.26)	(0.79)	(0.34)	-	(0.53)	(0.04)	-	(1.96)	(104.76)
As at March 31, 2024	595.22	1,667.66	74.86	7.69	88.41	24.99	81.06	2,539.89	15.83
Accumulated depreciation									
As at April 01, 2022	63.30	383.08	18.15	3.98	17.64	7.87	21.40	515.42	-
Charge for the year	18.57	133.50	6.05	0.89	7.35	3.87	6.12	176.35	-
Disposals/ transfers	-	-	-	-	-	-	(0.31)	(0.31)	-
As at March 31, 2023	81.87	516.58	24.20	4.87	24.99	11.74	27.21	691.46	-
Charge for the year	18.67	160.68	6.36	1.00	7.74	5.68	8.03	208.16	-
Disposals/ transfers	(0.04)	(0.29)	(0.19)	-	(0.26)	(0.04)	-	(0.82)	-
As at March 31, 2024	100.50	676.97	30.37	5.87	32.47	17.38	35.24	898.80	-
Net Block									
As at March 31, 2023	511.90	1,064.70	49.62	2.12	63.56	6.82	46.91	1,745.63	-
As at March 31, 2024	494.72	990.69	44.49	1.82	55.94	7.61	45.82	1,641.09	15.83

Notes:

(1) On transition to Ind AS (i.e. April 01, 2020), the Company has elected to continue with the carrying value of all Property, plant and equipment measured as per the previous GAAP and use that carrying value as the deemed cost of Property, plant and equipment.

(2) During the year ended March 31, 2023, the management of the Company performed an operational review of its property, plant and equipment and intangible assets which resulted in changes in expected usage of assets. Considering the trend of scale of operations the Company, the management expects to derive future economic benefits from its property, plant and equipment and intangible assets evenly throughout the useful lives of the assets. Based on above assessment, the depreciation method is changed from written down value method to straight line method. The effect of this change on actual and expected depreciation expense, in previous year, current year and future year, is as follows:

Particulars	(₹ in Million)		
	For the year ended March 31, 2023	For the year ending March 31, 2024	For the year ending March 31, 2025
Decrease in depreciation expense:			
- Property, plant and equipment	245.89	146.70	65.28
- Intangible assets	3.28	8.56	1.07

(3) Refer note 16 for the charge / hypothecation created on the property, plant and equipment against borrowing facilities availed by the Company.

(4) Capital work-in-progress ageing schedule is as below:*

Particulars	(₹ in Million)				
	Amount in CWIP for a period of				
	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
Projects in progress	15.83	-	-	-	15.83
Projects temporarily suspended	-	-	-	-	-
Total	15.83	-	-	-	15.83

* Considering CWIP balance as at March 31, 2023 is Nil ageing disclosure is not applicable.

(5) There are no Capital work-in-progress whose completion is overdue or has exceeded its cost compared to its original plan as at March 31, 2024 and March 31, 2023.

(This space has been intentionally left blank.)



Handwritten signature in blue ink.



Handwritten signature in blue ink.

4 Intangible assets

(₹ in Million)	
Particulars	Computer software
Gross Block (at cost / deemed cost)	
As at April 01, 2022	5.98
Additions	25.52
Disposals / transfers	(2.89)
As at March 31, 2023	28.61
Additions	6.27
As at March 31, 2024	34.88
Accumulated amortisation	
As at April 01, 2022	3.34
Charge for the year	4.67
Disposals / transfers	(2.89)
As at March 31, 2023	5.12
Charge for the year	10.86
As at March 31, 2024	15.98
Net block	
As at March 31, 2023	23.49
As at March 31, 2024	18.90

Notes:

(1) On transition to Ind AS (i.e. April 01, 2020), the Company has elected to continue with the carrying value of all Intangible assets measured as per the previous GAAP and use that carrying value as the deemed cost of Intangible assets.

5 Investment property

(₹ in Million)	
Particulars	Land
Gross Block (at cost)	
As at April 01, 2022	-
Additions	-
As at March 31, 2023	-
Additions	329.69
As at March 31, 2024	329.69
Accumulated depreciation	
As at April 01, 2022	-
Charge for the year	-
As at March 31, 2023	-
Charge for the year	-
As at March 31, 2024	-
Net block	
As at March 31, 2023	-
As at March 31, 2024	329.69

Notes:

(1) There is no amount recognised in profit or loss for investment property.

(2) As at 31 March 2024, the fair values of the properties are ₹ 418.70 million. These valuations are based on valuations performed by S Lakshman, a registered valuer as defined under rule 2 of Companies (Registered Valuers and Valuation) Rules, 2017. The main inputs considered by the valuer are government guideline rates, property location, market research and trends and comparable values as appropriate.

(3) The Company has no restrictions on the realisability of its investment property and no contractual obligations to purchase, construct or develop investment property or for repairs, maintenance and enhancements. Further, the Company has not determined the future use of the property purchased as at the year end.

(4) Fair value hierarchy disclosures for investment property have been provided in Note 38.



6 Non-current investments

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Investments (Unquoted) (measured at cost)		
A) In equity shares of subsidiaries:		
Decipher Life Sciences Private Limited		
- 10,000 (March 31, 2023: 10,000) shares of ₹ 10 each, fully paid-up (at cost less impairment on investment ₹ 0.11 Million (March 31, 2023: ₹ 0.11 Million))	-	-
Remfud Bioenergy Private Limited		
- 10,000 (March 31, 2023: 10,000) shares of ₹ 10 each, fully paid-up (at cost less impairment on investments ₹ 0.10 Million (March 31, 2023: ₹ 0.10 Million))	-	-
Bigtec Healthcare Private Limited		
- 5,000 (March 31, 2023: 5,000) shares of ₹ 10 each, fully paid-up (at cost less impairment on investments ₹ 0.05 Million (March 31, 2023: ₹ 0.05 Million))	-	-
Bigtec Private Limited	87.20	87.20
- 4,471,177 (March 31, 2023: 4,471,177) shares of ₹ 10 each, fully paid-up		
Prognosis Medical Systems Private Limited ('PMS') (refer note a)	144.60	144.60
- 890,103 (March 31, 2023: 890,103) shares of ₹ 10 each, fully paid-up		
Prognosis Healthcare Private Limited ('PHPL') (refer note c)	-	-
- 7,791 (March 31, 2023: Nil) shares of ₹ 10 each, fully paid-up (at cost less impairment on investment ₹ 102.62 Million (March 31, 2023: ₹ Nil))		
B) In compulsorily convertible preference shares of subsidiary in the nature of equity:		
Prognosis Medical Systems Private Limited (refer note a)	246.11	246.11
- 1,514,872 (March 31, 2023: 1,514,872) 0.0001% compulsorily convertible preference shares of ₹ 10 each, fully paid-up		
C) In compulsorily convertible preference shares of associate in the nature of equity:		
Chayagraphics (India) Private Limited ('CGIPL') (refer note b)	60.00	60.00
- 415,622 (March 31, 2023: 415,622) 0.0001% compulsorily convertible preference shares of ₹ 10 each, fully paid-up		
Investments at fair value through profit and loss account		
D) Investment in unquoted equity shares		
The Saraswat Co-operative Bank Limited	0.03	0.03
- 2,500 (March 31, 2023: 2,500) shares of ₹ 10 each, fully paid-up		
Total non-current investments	537.94	537.94
Aggregate book value of unquoted investments	640.82	538.20
Aggregate amount of impairment in value of investments	102.88	0.26

Notes:

a During the year ended March 31, 2023, the Company, PMS, promoters and other existing shareholders of PMS have entered into share purchase agreement and shareholder agreement (collectively referred as "PMS SHA agreement") pursuant to which the Company has acquired 890,103 Class A equity shares (face value : ₹ 10) from the existing shareholders for a cash consideration amounting to ₹ 144.60 Million and subscribed 1,514,872 0.0001% compulsorily convertible preference shares (face value : ₹ 10) for a cash consideration amounting to ₹ 246.11 Million in PMS. The 0.0001% compulsorily convertible preference shares shall be convertible into Class A equity shares as per the terms as mentioned in PMS SHA agreement. PMS has become subsidiary of the Company pursuant to such acquisition. PMS is engaged in manufacturing of X-ray equipments, single / dual detector solutions, etc. Also refer note 36.

Prior to investment by the Company, there was a fraud/misappropriation of earnest money deposit ('EMD') of ₹ 199.00 Million (net of recovery) in PMS. The fraud was committed by two individuals who floated a fake tender by forging signature of high ranking Government officials of West Bengal. The Company is confident of recovery of the remaining aforesaid EMD, based on the various legal actions taken by PMS and the management of the Company. Further, based on business plan as approved by the Board of the Company, and keeping in view the strategic long term nature of investment, the management of the Company is of the view that the carrying value of investments in PMS as at March 31, 2024 is appropriate.

b During the year ended March 31, 2023, the Company, CGIPL and promoters have entered into shareholder agreement (referred as "CGIPL SHA agreement") pursuant to which the Company has subscribed 415,622 0.0001% compulsorily convertible preference shares (face value : ₹ 10) in CGIPL. The 0.0001% compulsorily convertible preference shares shall be convertible into equity shares as per the terms as mentioned in CGIPL SHA agreement and accordingly, CGIPL has become associate of the Company pursuant to such acquisition. As per the terms of the agreement, the Company has subscribed to 0.0001% compulsorily convertible preference shares of CGIPL for a cash consideration amounting to ₹ 60.00 Million.

Further, based on business plan as approved by the Board of the Company, and keeping in view the strategic long term nature of investment, the management of the Company is of the view that the carrying value of investments in CGIPL as at March 31, 2024 is appropriate. Also refer note 36.

During the year ended March 31, 2024, out of the investment made in CGIPL, ₹ 58.62 Million was utilised by CGIPL for investing in Chayagraphics Healthcare Private Limited ('CGHC'). Refer note 42(vii) for further details.

c During the year ended March 31, 2024, the Company, PHPL, promoters and other existing shareholders of PHPL have entered into share purchase agreement and shareholder agreement (collectively referred as "PHPL SHA agreement") pursuant to which the Company has acquired 7,791 equity shares (face value : ₹ 10) from the existing shareholders for a cash consideration amounting to ₹ 102.62 Million in PHPL. PHPL has become subsidiary of the Company pursuant to such acquisition. PHPL is engaged in designing Telemedicine Solutions and providing technology based services in field of healthcare. Also refer note 36.

The management of the Company, based on its internal assessment with regard to future operations, has made a provision for other than temporary diminution in the value of investment in PHPL amounting to ₹ 102.62 million during the year ended March 31, 2024 and has disclosed the same as "Impairment on investments" under exceptional items in the accompanying Standalone Ind AS financial statements of the Company for the year ended March 31, 2024.



7 Other financial assets

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Unsecured, considered good unless otherwise stated		
Non-current		
Financial instruments at amortised cost		
Security deposits	11.25	7.46
Non-current bank balances (refer note 12)	155.98	267.29
Total other non-current financial assets	167.23	274.75
Current		
Financial instruments at amortised cost		
Security deposits	1.03	1.31
Interest accrued on fixed deposits	1.99	1.49
Interest accrued on loans (also refer note 36)	22.04	50.25
Other receivables	75.01	108.04
Total other current financial assets	100.07	161.09

8 Loans - Current (Unsecured)

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Loans to related parties (refer note 36)	50.00	122.49
Total current loans	50.00	122.49

- Loans are non-derivative financial assets which are interest bearing for the Company and are measured at amortised cost. The carrying value may be affected by changes in the credit risk of the counterparties.
- The Company has not granted any advances in the nature of loans to promoters, KMPs and the related parties (as defined under the Companies Act, 2013) either severally or jointly other than as disclosed below:
- Loans to related parties (as defined under the Companies Act, 2013) either severally or jointly with any other person that are repayable on demand or without specifying any terms or period of repayment are disclosed in note 36.

9 Non-current tax assets (net)

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Advance income-tax (net of provision for current tax)	130.56	289.81
Total non-current tax assets (net)	130.56	289.81

10 Trade receivables

	(₹ in Million)		
	March 31, 2024	March 31, 2023	
Trade receivables- Unsecured, considered good	3,602.55	1,733.11	
Trade receivables which have significant increase in credit risk	290.09	40.14	
Trade receivables - Unsecured, credit impaired	-	-	
(A)	3,892.64	1,773.25	
Impairment allowance (allowance for bad and doubtful debts)			
Trade receivables which have significant increase in credit risk	(290.09)	(40.14)	
Trade receivables - Unsecured, credit impaired	-	-	
(B)	(290.09)	(40.14)	
Total trade receivables	(A + B)	3,602.55	1,733.11

Notes :

- No trade or other receivable are due from directors or other officers of the Company either severally or jointly with any other person. Nor any trade or other receivables are due from firms or private companies respectively in which any director is a partner, a director or a member. Also refer note 36.
- Trade receivables are non-interest bearing and are generally on terms of upto 90 days.
- The Company's exposure to credit and currency risk, and loss allowances are disclosed in note 38.
- Movement in expected credit loss allowance under simplified approach are provided in the table below:

Expected credit loss allowance

	(₹ in Million)	
	March 31, 2024	March 31, 2023
At the beginning of the year	40.14	39.23
Provision made during the year	249.95	6.40
(Utilised / reversed) during the year	-	(5.49)
At the end of the year	290.09	40.14

- There are no unbilled receivables, hence the same is not disclosed in the ageing schedule.



10.1 Trade receivables ageing schedule

As at March 31, 2024							(₹ in Million)
Particulars	Outstanding for following periods from due date of invoice					Total	
	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	More than 3 years		
(i) Undisputed trade receivables - considered good	3,152.75	200.75	211.61	37.44	-	3,602.55	
(ii) Undisputed trade receivables - which have significant increase in credit risk	76.60	2.92	62.20	114.84	33.53	290.09	
(iii) Undisputed trade receivables - credit impaired	-	-	-	-	-	-	
(iv) Disputed trade receivables - considered good	-	-	-	-	-	-	
(v) Disputed trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	
(vi) Disputed trade receivables - credit impaired	-	-	-	-	-	-	
Total	3,229.35	203.67	273.81	152.28	33.53	3,892.64	

As at March 31, 2023							(₹ in Million)
Particulars	Outstanding for following periods from due date of invoice					Total	
	Less than 6 months	6 months to 1 year	1-2 years	2-3 years	More than 3 years		
(i) Undisputed trade receivables - considered good	1,532.79	5.71	168.54	26.07	-	1,733.11	
(ii) Undisputed trade receivables - which have significant increase in credit risk	0.10	4.07	27.20	4.63	4.14	40.14	
(iii) Undisputed trade receivables - credit impaired	-	-	-	-	-	-	
(iv) Disputed trade receivables - considered good	-	-	-	-	-	-	
(v) Disputed trade receivables - which have significant increase in credit risk	-	-	-	-	-	-	
(vi) Disputed trade receivables - credit impaired	-	-	-	-	-	-	
Total	1,532.89	9.78	195.74	30.70	4.14	1,773.25	

(This space has been intentionally left blank)



Handwritten signature and initials.



11 Inventories (valued at lower of cost and net realisable value)

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Raw materials and components ^{1,2}	1,450.04	1,415.16
Work-in-progress ²	886.11	1,026.19
Finished goods ²	537.25	811.57
Trade goods	52.85	24.60
Total inventories	2,926.25	3,277.52

Notes:

- Includes goods in transit of ₹ 77.98 Million (March 31, 2023 : ₹ Nil).
- The closing balance of inventories is net of provision of ₹ 194.14 Million (March 31, 2023 : ₹ 55.81 Million).

12 Cash and cash equivalents and Other bank balances

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Cash and cash equivalents		
- On current accounts ²	182.47	42.92
Cash on hand	0.15	0.22
Total Cash and cash equivalents	182.62	43.14
Other bank balances		
- Deposits with original maturity more than 3 months but less than 12 months	-	2.64
- Margin money deposits ¹	155.98	267.29
(A)	155.98	269.93
Amounts disclosed under other non-current financial assets (refer note 7)	(155.98)	(267.29)
(B)	(155.98)	(267.29)
Total other bank balances	(A+B)	-

- A lien has been created over the deposits of ₹ 155.98 Million (March 31, 2023: ₹ 267.29 Million) towards performance bank guarantee given to its customers.
- Cash and cash equivalents include an amount of ₹ 84.53 Million (March 31, 2023: ₹ Nil) which is restricted to be spent on CSR activities. Also refer note 41.
- For the purpose of statement of cash flows, cash and cash equivalents comprise of the following:

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Balances with banks		
- On current accounts	182.47	42.92
Cash on hand	0.15	0.22
Bank overdraft (refer note 16)	(408.19)	(89.66)
	(225.57)	(46.52)

(This space has been intentionally left blank)



G. M.



13 Other assets

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Non-current		
Capital advances		
Unsecured, considered good	31.94	30.37
Other advances (Unsecured, considered good)		
Balances with statutory / government authorities	280.00	-
	311.94	30.37
Current		
Advances other than capital advances		
Unsecured, considered good	233.51	246.42
Unsecured, credit impaired	59.31	-
(A)	292.82	246.42
Impairment allowance		
Unsecured, credit impaired	(59.31)	-
(B)	(59.31)	-
Total advances other than capital advances	(C = A+B) 233.51	246.42
Other advances (Unsecured, considered good)		
Prepaid expenses	5.76	4.34
Balances with statutory / government authorities	186.45	516.83
Total other advances	(D) 192.21	521.17
Total other current assets	(C+D) 425.72	767.59

(This space has been intentionally left blank)



Handwritten signature in blue ink.



14 Share Capital

Authorized share capital

Equity shares of ₹ 10 each (March 31, 2023 : ₹ 10 each)

As at April 01, 2022

Increase / (decrease) during the year

As at March 31, 2023

Increase / (decrease) during the year

As at March 31, 2024

Equity Shares		Preference Shares	
Number (in Million)	₹ in Million	Number (in Million)	₹ in Million
11.90	119.00	0.30	3.00
-	-	-	-
11.90	119.00	0.30	3.00
-	-	-	-
11.90	119.00	0.30	3.00

(a) Issued share capital

Equity shares of ₹ 10 each (March 31, 2023 : ₹ 10 each)

Issued, subscribed and fully paid up

As at April 01, 2022

Changes during the year (refer note f)

As at March 31, 2023

Changes during the year

As at March 31, 2024

Equity shares	
Number (in Million)	₹ in Million
2.24	22.46
0.01	0.08
2.25	22.54
-	-
2.25	22.54

(b) Terms / rights attached to equity shares

The Company has only one class of equity shares having par value of ₹ 10 per share. Each holder of equity shares is entitled to one vote per share. The Company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(c) Details of Shareholders holding more than 5% shares in the Company

Name of the shareholder	March 31, 2024		March 31, 2023	
	Number of Shares	% Holding	Number of Shares	% Holding
Equity shares of ₹ 10 each fully paid up				
Exxora Trading LLP	929,752	41.26%	929,752	41.26%
India Business Excellence Fund III	305,720	13.57%	305,720	13.57%
V Sciences Investments Pte Limited	201,403	8.94%	201,403	8.94%
Mr. N D Prabhu	-	-	122,291	5.43%
Mr. J. Guru Dutt & Mrs. Sandhya Guru Dutt	122,197	5.42%	122,197	5.42%
Mr. Chandrasekhar Bhaskaran Nair & Mrs. Anita Chandrasekhar	122,197	5.42%	122,197	5.42%
Mr. G Sampathgiri & Mrs. Jayshree Sampathgiri	122,197	5.42%	122,197	5.42%
Mr. G M. Kim	152,677	6.77%	122,104	5.42%

As per records of the Company, including its register of shareholders / members and other declarations received from shareholders regarding beneficial interest, the above shareholding represents both legal and beneficial ownerships of shares.

(d) Details of shares held by promoters

As at March 31, 2024

Name of the Promoter ¹	No. of shares at the beginning of the year	Change during the year	No. of shares at the end of the year	% of Total Shares	% change during the year
Exxora Trading LLP	929,752	-	929,752	41.26%	-
Mr. Chandrasekhar Bhaskaran Nair & Mrs. Anita Chandrasekhar	122,197	-	122,197	5.42%	-
Total	1,051,949	-	1,051,949	46.68%	-

As at March 31, 2023

Name of the Promoter	No. of shares at the beginning of the year	Change during the year	No. of shares at the end of the year	% of Total Shares	% change during the year
Exxora Trading LLP	939,528	(9,776)	929,752	41.26%	(1.04%)
Mr. Chandrasekhar Bhaskaran Nair & Mrs. Anita Chandrasekhar	143,594	(21,397)	122,197	5.42%	(14.90%)
Total	1,083,122	(31,173)	1,051,949	46.68%	(2.88%)

Notes:

1. The above shareholding disclosure of promoters is based on the MGT-7 filed by the Company.

(e) Shares reserved for issue under contract / commitment

For details of shares reserved for issuance on conversion of share warrant, refer note 15(b).

(f) During the year ended March 31, 2023, the Company has allotted 7,340 equity shares of face value ₹ 10 each at a premium of ₹ 54,485.91 each in favor of V Sciences Investments Pte. Ltd. Further, certain shareholder of the Company has also transferred 194,063 equity shares to V Sciences Investments Pte. Ltd. for a consideration as agreed between the parties. Such allotment is pursuant to the approval of the Board of Directors in the board meeting and the special resolution passed by the Shareholders in the extra-ordinary general meeting held during the year ended March 31, 2023.

(g) The Company has not allotted any fully paid equity shares by way of bonus shares nor has bought back any class of equity shares during the period of five years immediately preceding the balance sheet date nor has issued shares for consideration other than cash.

(This space has been intentionally left blank)



(Handwritten signature)



(Handwritten signature)

15 Other equity

a) Reserves and surplus

Securities premium

Balance as at April 01, 2022 *

Charges during the year (refer note 14(f))

Balance as at March 31, 2023

Charges during the year

Balance as at March 31, 2024

₹ in Million

1,548.75

399.93

1,948.68

-

(A) 1,948.68

* Balance as at April 01, 2022, is net of Net Debt adjustment done post conversion of 10% Optionally Convertible Secured Redeemable Debentures ('OCD') as per the terms of the Investment Agreement and amendments thereto during the year ended March 31, 2022. Also refer note 15.4

Amalgamation reserve

Balance as at April 01, 2022

Charges during the year

Balance as at March 31, 2023

Charges during the year

Balance as at March 31, 2024

92.78

-

92.78

-

(B) 92.78

Retained earnings

Balance as at April 01, 2022

Profit for the year

Add: Re-measurement gains / (losses) on defined benefit plans (net of taxes)

Balance as at March 31, 2023

Profit for the year

Add: Re-measurement (losses) / gains on defined benefit plans

Balance as at March 31, 2024

5,016.58

155.46

1.45

5,173.49

1,111.06

(0.96)

(C) 6,283.59

Other reserves

Balance as at April 01, 2022

Charges during the year

Balance as at March 31, 2023

Charges during the year

Balance as at March 31, 2024

148.75

-

148.75

-

(D) 148.75

Total reserves and surplus

Balance as at March 31, 2023

Balance as at March 31, 2024

7,363.70

(A+B+C+D) 8,473.80

(This space has been intentionally left blank)



G K.



15 Other Equity (continued)

Nature and purpose of reserves

15.1 Securities premium

Securities premium is used to record the premium on issue of shares. The reserve can be utilised only for limited purposes such as issuance of bonus shares in accordance with the provisions of the Companies Act, 2013

15.2 Amalgamation reserves

Represents reserve recognised during the year ended March 31, 2016 pursuant to the scheme of amalgamation of Bigtec India Private Limited with the Company.

15.3 Retained earnings

Retained earnings are the profit / (loss) that the Company has earned / incurred till date, less any transfers to general reserve, dividends or other distributions paid to shareholders. Retained earnings include re-measurement loss / (gain) on defined benefit plans, net of taxes that will not be reclassified to Statement of Profit and Loss

15.4 Other reserves

During the year ended March 31, 2020, the Company issued 10% Optionally Convertible Secured Redeemable Debentures ('OCD') in three tranches, of face value of ₹ 10,000 each to India Business Excellence Fund III (IBEF III) ('the Investor') in accordance with the terms of investment agreement dated September 10, 2019 and amendments thereto (collectively referred as "the Investment agreement").

Investor had an option for redemption or conversion of OCDs into equity shares and further, had an exit right including right requiring the Company to buy back the securities held by them. Considering the buy-back obligation of the Company and not meeting fixed to fixed criteria, the OCDs, at inception, were recorded as liability at fair value through profit and loss. Further, subsequently on April 01, 2021, the Investor had agreed to waive the buy-back rights granted to them in Investment agreement. Hence, upon conversion the fair value loss of ₹ 148.75 Million was transferred to other equity during the year ended March 31, 2022.

During the year ended March 31, 2022, based on the right exercised by the Investor on May 27, 2021 and pursuant to the approval of Board of Directors in the board meeting held on May 29, 2021, 140,000 OCDs were converted into 193,138 equity shares of face value of ₹ 10 each at a premium. Further, pursuant to the communication by the Investor on May 27, 2021 and approval of the Board of Directors in the board meeting held on May 29, 2021 and approval of the Shareholders in the extra-ordinary general meeting held on May 31, 2021, 31,494 equity shares of face value of ₹ 10 each were issued to the Investor as Fourth Tranche Securities at a premium for an amount aggregating to ₹ 205.15 Million (Fourth Tranche Investment Amount) to meet the minimum shareholding commitment for investors.

Post conversion of OCDs and issuance of Fourth Tranche Securities, due to Certified Net Debt derived being more than the Projected Net Debt, the Company refunded the surplus premium paid by the investor amounting to ₹ 165.01 Million as per the terms of Investment agreement.

b) Money received against share warrants

Balance as at April 01, 2022
Changes during the year
Balance as at March 31, 2023
Changes during the year
Balance as at March 31, 2024

₹ in Million
3.50
-
3.50
-
3.50

Terms / rights attached to share warrant:

During the year ended March 31, 2020, pursuant to the approval of the Board of Directors and approval of the Shareholders in the extra-ordinary general meeting, the Company had issued 5,000 share warrants of ₹ 2,000 each with warrant subscription price of ₹ 700 each by way of private placement under the provisions of Companies Act, 2013 and provisions of all other applicable laws and regulations. The Company and promoters shall cause the Company to convert the warrants (all and not less than all) into equity shares as per Investment agreement and amendments thereto ('the Investment agreement') referred in note 15. During the year ended March 31, 2023 as per the share purchase and share subscription agreement entered on August 16, 2022, the said share warrants can be exercised in accordance with the terms of warrants subscription agreement, to receive 1,535 equity shares. Also, refer note 48.

Total other equity (a+b)

Balance as at March 31, 2023
Balance as at March 31, 2024

7,367.20
8,477.30

(This space has been intentionally left blank)



Handwritten signature



16 Borrowings

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Non Current		
Vehicle loans from bank (secured)		
Vehicle loans (refer note a)	8.50	9.85
Loans from financial institutions (secured)		
Term loans (refer note e)	142.73	-
Total non-current borrowings	(A) 151.23	9.85
Current		
Loans from bank and financial institutions		
Bank overdraft (refer note c) (secured)	408.19	89.66
Loan (refer note d) (secured)	-	352.78
Loans from related parties (unsecured)		
Loans (refer note b)	0.37	73.89
Current maturities of long term borrowings		
Vehicle loans from bank (secured)		
Vehicle loans (refer note a)	7.19	17.16
Term loans (refer note e)	97.35	-
Total current borrowings	(B) 513.10	533.49
Total financial liabilities - borrowings	(A+B) 664.33	543.34
The above amount includes		
Secured borrowings	663.96	469.45
Unsecured borrowings	0.37	73.89

Notes:

a. Secured Indian rupee vehicle loans from banks

As at March 31, 2024, the vehicle loans from the Banks amounting to ₹ 15.69 Million (March 31, 2023: ₹ 27.01 Million) carries an effective interest rate ranging between 7.42% to 9.24% p.a. (March 31, 2023: 7.42% to 9.93%) and is secured by the hypothecation of the respective vehicle. The loan is repayable in 36 to 39 equal monthly instalments.

During the year ended March 31, 2024, the Company has defaulted in repayment of principal and interest in the following instances of vehicle loans:

Name of lender	Amount not paid on due date	No. of days delay or unpaid	Remarks
HDFC Bank	₹ 0.03 Million	15 days	Procedural Delay

b. Loans from related parties (also refer note 36)

Loans from related parties include a loan of ₹ 0.37 Million (March 31, 2023: ₹ 73.89 Million) from Mr. Sriram Natarajan which carries an interest rate ranging from 9% p.a. to 12% p.a. and was initially repayable on conversion of OCDs. Post conversion of OCDs during the year ended March 31, 2022, the same is repayable on demand.

c. Bank overdraft

Bank overdraft from banks of carries an interest rate of 3-6 month MCLR + Spread 0.15% p.a. - 0.30% p.a. and is secured by way of first ranking pari passu pledge of current assets (both current & future), property plant and equipment (both current & future), intangible assets (both current & future), first ranking pari passu charge on immovable property L42 and L46 and undated cheque for the facility amount.

d. Short-term Loan from bank

Short-term Loan from Yes Bank Limited of ₹ Nil (March 31, 2023: ₹ 352.78 Million) carried an interest rate of 1 month MCLR + Spread 0.25% p.a. and was secured by way of first ranking pari passu pledge of current assets (both current & future), plant & machinery excluding vehicles (both current & future) and undated cheque for the facility amount. The loan outstanding were repaid entirely during the year ended March 31, 2024.

e. Term Loan

Term Loan from Tata Capital Limited of ₹ 240.08 Million (March 31, 2023: ₹ Nil) carries an interest rate of 10.25% p.a. and is secured by way of first exclusive charge on collateral of investment property. The loan is repayable in 36 monthly instalments commencing from September 10, 2023 and ending on August 10, 2026.

f. The Company does not have a process of preparing the financial statements on a quarterly basis. Accordingly, the quarterly statements filed by the Company with such banks cannot be reconciled with the audited/ reviewed books of accounts of the Company.

(This space has been intentionally left blank)



17 Net employee defined benefit liabilities

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Non-current		
Provision for employee benefits:		
Provision for gratuity (refer note 33)	3.21	1.78
	<u>3.21</u>	<u>1.78</u>
Current		
Provision for employee benefits:		
Provision for gratuity (refer note 33)	3.50	3.50
	<u>3.50</u>	<u>3.50</u>

18 Provisions

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Current		
Provision for compensated absences	16.08	10.77
Provision for warranty ¹	141.96	80.87
	<u>158.04</u>	<u>91.64</u>

1. The Company provides warranties for its products, systems and services, undertaking to repair or replace the items that fail to perform satisfactorily during the warranty period. Provision represents the amount of the expected cost based on technical evaluation and past experience of meeting such obligations. It is expected that this expenditure will be incurred over the contractual warranty period.

Details of changes in warranty provision during the year

Particulars	(₹ in Million)	
	March 31, 2024	March 31, 2023
At the beginning of the year	80.87	37.31
Add : Additions made during the year	111.71	59.40
Less : Amounts utilised during the year	(50.62)	(15.84)
At the end of the year	<u>141.96</u>	<u>80.87</u>

(This space has been intentionally left blank)



Handwritten signature in blue ink.



Handwritten signature in blue ink.

19 Other financial liabilities

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Current		
Employee related payables (refer note 36)	80.53	83.84
Payable towards capital goods	15.56	20.14
	96.09	103.98

20 Other liabilities

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Current		
Contract liabilities - Deferred revenue (refer note 22)	73.22	94.45
Advance from customers (refer note 22)	52.89	58.13
Statutory dues payable	83.03	50.15
Liability towards corporate social responsibility (refer note 41)	140.67	84.53
	349.81	287.26

1. Contract liability represents the aggregate amount of the transaction price allocated to the performance obligation that are unsatisfied as at the end of the reporting period.

21 Trade payables

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Carried at amortised cost		
Total outstanding dues of micro enterprises and small enterprises ^{1,2}	49.28	49.84
Total outstanding dues of creditors other than micro enterprises and small enterprises ¹	909.87	695.87
	959.15	745.71

The above amount includes:

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Trade payables to related parties (refer note 36)	209.43	-
Trade payables to others	749.72	745.71
	959.15	745.71

Notes:

1. Trade payables are non-interest bearing and are normally settled on terms upto 90 days.

2. Trade payables and capital creditors include due to suppliers under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED Act, 2006). Amount due to suppliers under the MSMED Act, 2006 has been determined to the extent such parties have been identified on the basis of information available with and filings made by the Company. The Company has not received any claim for interest from any supplier as at the balance sheet date. Further in view of the management, the impact of interest, if any, that may be payable in accordance with the provisions of the MSMED Act 2006 is not expected to be material. The disclosure pursuant to the said act is made under note 21.1.

21.1 Disclosure as per the MSMED Act, 2006

	(₹ in Million)	
The principal amount and the interest due thereon remaining unpaid to any supplier as at the end of each accounting year:	March 31, 2024	March 31, 2023
- Principal amount due to micro and small enterprises	33.21	36.27
- Interest due on above	0.23	0.82
The amount of interest paid by the buyer in terms of section 16 of the MSMED Act 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act 2006	2.26	3.98
The amount of interest accrued and remaining unpaid at the end of each accounting year.	2.49	4.80
The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the MSMED Act, 2006	16.07	13.58

(This space has been intentionally left blank)



Handwritten signatures in blue ink.

21.2 Trade payables ageing Schedule

As at March 31, 2024

Particulars	Unbilled	Outstanding for following periods from due date of payment*				Total
		Less than 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed dues of micro enterprises and small enterprises	17.95	30.89	0.20	0.24	-	49.28
Undisputed dues of creditors other than micro enterprises and small enterprises	213.86	682.94	5.32	4.22	3.53	909.87
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
Total	231.81	713.83	5.52	4.46	3.53	959.15

As at March 31, 2023

Particulars	Unbilled	Outstanding for following periods from due date of payment*				Total
		Less than 1 year	1-2 years	2-3 years	More than 3 years	
Undisputed dues of micro enterprises and small enterprises	-	48.71	1.13	-	-	49.84
Undisputed dues of creditors other than micro enterprises and small enterprises	193.80	478.33	19.90	-	3.84	695.87
Disputed dues of micro enterprises and small enterprises	-	-	-	-	-	-
Disputed dues of creditors other than micro enterprises and small enterprises	-	-	-	-	-	-
Total	193.80	527.04	21.03	-	3.84	745.71

*Note: The management has considered transaction date as the basis for determining the ageing of the trade payables.

(This space has been intentionally left blank)



[Handwritten signature]



[Handwritten signature]

22 Revenue from operations

22.1 Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contracts with customers:

	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Revenue from contracts with customers		
Sale of products		
Finished Goods	7,382.41	3,159.59
Traded goods	42.91	5.78
Other operating revenue	137.83	100.35
Total revenue from contracts with customers	7,563.15	3,265.72
India	6,753.28	2,778.62
Outside India	809.87	487.10
Total revenue from contracts with customers	7,563.15	3,265.72

22.2 Timing of revenue recognition

	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Service transferred over time		
- Other operating revenue	128.12	100.35
Service transferred at a point in time		
- Other operating revenue	9.71	-
Goods transferred at a point in time		
- Sale of products	7,425.32	3,165.37
	7,563.15	3,265.72

22.3 Contract Balances

	(₹ in Million)		
	March 31, 2024	March 31, 2023	April 01, 2022
Trade receivables :-			
- Current (Gross)	3,892.64	1,773.25	2,445.19
- Impairment allowance	(290.09)	(40.14)	(39.24)
Contract liabilities:-			
Advance from customers			
- Current	52.89	58.13	27.81
Deferred revenue:			
- Current (refer note a below)	73.22	94.45	28.30

a) Movement in Contract Liabilities - Deferred Revenue

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Opening balance	94.45	28.30
Add: Revenue to be recognized from performance obligations to be satisfied in succeeding years	19.52	81.46
Less: Revenue recognized that was included in contract liability at the beginning of the year	(40.75)	(15.31)
Closing balance	73.22	94.45

22.4 Reconciliation of revenue as recognised in the Statement of profit and loss with the contracted price:

	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Revenue as per contracted price	7,739.59	3,354.41
Adjustments		
Extended warranties	(73.22)	(94.45)
Liquidated damages	(2.93)	19.63
Tender processing fees	(19.09)	-
Discounts	(81.20)	(13.87)
Revenue from contract with customers	7,563.15	3,265.72



Handwritten signature in blue ink.



Handwritten signature in blue ink.

23 Other income

Interest income on bank deposits
Duty drawback
Gain on account of foreign exchange fluctuation (net)
Interest income on loan (refer note 36)
Gain on sale / discard of property, plant and equipment
Miscellaneous income
Total other income

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
7.71	13.91
9.87	7.57
7.75	-
36.47	51.18
-	0.07
3.42	8.28
65.22	81.01

24 Cost of material and components consumed

Inventory at the beginning of the year
Add: Purchases
Less: inventory at the end of the year
Cost of material and components consumed

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
1,415.16	1,522.96
2,474.13	1,664.16
(1,450.04)	(1,415.16)
2,439.25	1,771.96

25 Decrease / (increase) in inventories of finished goods, work-in-progress and traded goods

Opening balance

Work-in-progress
Finished goods
Traded goods
Total opening balance

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
1,026.19	717.87
811.57	693.96
24.60	22.82
1,862.36	1,434.65

Closing balance

Work-in-progress
Finished goods
Traded goods
Add: Provision for inventory disclosed as exceptional item
Total closing balance

886.11	1,026.19
537.25	811.57
52.85	24.60
168.59	-
1,644.80	1,862.36

Total decrease / (increase) in inventories of finished goods, work-in-progress and traded goods

217.56	(427.71)
---------------	-----------------

26 Employee benefit expenses

Salaries, wages and bonus
Gratuity expenses (refer note 33)
Contribution to provident and other funds *
Staff welfare expenses
Total employee benefit expenses

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
357.18	316.18
4.98	4.34
16.57	13.73
7.29	5.87
386.02	340.12

* Other funds represents contribution to labour welfare fund, profession tax and employees' state insurance corporation.

The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. Certain sections of the Code came into effect on May 3, 2023. However, the final rules / interpretation have not yet been issued. Based on a preliminary assessment, the Company believes the impact of the change will not be significant.

27 Depreciation and amortisation expenses

Depreciation of property, plant and equipment (refer note 3)
Amortisation of intangible assets (refer note 4)
Depreciation of right-of-use assets (refer note 34)
Total depreciation and amortisation expenses

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
208.16	176.35
10.86	4.67
16.95	12.86
235.97	193.88



Handwritten signature in blue ink.



Handwritten signature in blue ink.

28 Finance costs

Interest expenses (refer note 36)
Interest expense on micro and small enterprises (refer note 21.1)
Interest on lease liabilities (refer note 34)
Interest on income tax
Bank charges
Total finance costs

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
58.96	49.59
2.49	4.80
2.77	2.80
8.27	-
3.59	2.25
76.08	59.44

29(a) Other expenses

Royalty expenses (refer note 36)
Manpower cost
Freight expenses
Commission expenses
Travelling and conveyance
Power and fuel
Warranty expenses
Advertising and sales promotion
Legal and professional charges (refer note 36)
Payment to auditor*
Rent (refer note 34)
Rates and taxes
Loss on account of foreign exchange fluctuation (net)
Provision for doubtful debts, advances and other receivables (refer note 36)
Bad debts / advances written off
Loss on sale / discard of property, plant and equipment
Impairment on investments (refer note 36)
Corporate social responsibility expenses (refer note 41)
Miscellaneous expenses
Total other expenses

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
760.54	330.45
238.12	131.11
77.10	60.87
389.86	118.89
97.16	83.66
69.13	60.95
111.71	59.40
116.67	87.63
47.71	36.11
4.30	3.24
6.08	7.09
22.49	44.51
-	3.37
309.26	0.91
12.52	1.15
1.14	-
-	0.15
56.14	52.04
104.03	91.80
2,423.96	1,173.33

*Payment to auditor (exclusive of goods and services tax)

As auditor:
Statutory audit fees
Reimbursement of expenses

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
4.30	3.00
-	0.24
4.30	3.24

29(b) Exceptional items

Impairment on investment ¹
Provision for inventories ²
Total exceptional items

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
102.62	-
168.59	-
271.21	-

1. The management of the Company, based on its internal assessment with regard to future operations, has made an Impairment on investment in PHPL amounting to ₹ 102.62 million during the year ended March 31, 2024 and has disclosed the same as "Impairment on investment" under exceptional items in the accompanying Standalone Ind AS financial statements of the Company for the year ended March 31, 2024. Also refer note 6 and 36.

2. Based on internal assessment, the management of the Company has provided for inventories amounting to ₹ 168.59 Million with respect to excess inventories pertaining to COVID 19 pandemic.

(This space has been intentionally left blank)



Handwritten signature



30 Income tax

The Company is subject to income tax in India on the basis of Standalone Ind AS Financial Statements. Business loss can be carried forward for a maximum period of eight assessment years immediately succeeding the assessment year to which the loss pertains. Unabsorbed depreciation can be carried forward for an indefinite period.

Pursuant to the Taxation Law (Amendment) Ordinance, 2019 ('Ordinance') issued by Ministry of Law and Justice (Legislative Department) on September 20, 2019 which was effective from April 01, 2019, domestic companies had the option to pay income tax at 22% plus applicable surcharge and cess ('new tax regime') subject to certain conditions. The Company based on the projections had adopted the reduced rates of tax as per the Income Tax Act, 1961 from April 01, 2019.

a. Income tax expenses in the Standalone Ind AS statement of profit and loss and other comprehensive income consist of the following:

	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Ind AS statement of profit and loss		
(a) Current tax	574.15	69.54
(b) Deferred tax (credit) / charge	(170.17)	3.55
(c) Adjustment of tax relating to earlier years	3.85	-
	407.83	73.09
Other comprehensive income ('OCI')		
Deferred tax related to re-measurement losses on defined benefit plans	(0.32)	0.49
Income tax credit to OCI	(0.32)	0.49

b. Reconciliation of taxes to the amount computed by applying the statutory income tax rate to the income before taxes is summarised below:

	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Profit before tax	1,518.89	228.55
Applicable tax rates in India	25.17%	25.17%
Computed tax charge	382.30	57.53
Non-deductible expenses for tax purposes	20.33	17.18
Others	5.20	(1.62)
Total tax expense	407.83	73.09
Income tax reported in the Standalone Ind AS statement of profit and loss	407.83	73.09

c. Recognised deferred tax assets and liabilities

The following is the movement of deferred tax assets/liabilities presented in the balance sheet:

	(₹ in Million)			
For the Year ended March 31, 2024	Opening balance	Recognised in profit or loss	Recognised in OCI	Closing balance
A. Deferred tax liabilities				
Right-of-use assets	6.02	2.98	-	9.00
Property, plant and equipment and Intangible assets : Impact of difference between tax depreciation and depreciation / amortization charged for the purpose of financial reporting	(9.62)	11.08	-	1.46
Gross deferred tax liabilities	(3.60)	14.06	-	10.46
B. Deferred tax Assets				
Lease liabilities	7.15	2.42	-	9.57
Impact of expenditure charged to the statement of profit and loss in the current period but allowed for tax purposes on payment basis	50.73	181.95	0.32	233.00
Others	0.34	(0.14)	-	0.20
Gross deferred tax assets	58.22	184.23	0.32	242.77
C. Net deferred tax (Asset) / liabilities (A-B)	(61.82)	(170.17)	(0.32)	(232.31)

	(₹ in Million)			
For the Year ended March 31, 2023	Opening balance	Recognised in profit or loss	Recognised in OCI	Closing balance
A. Deferred tax liabilities				
Right-of-use assets	7.44	(1.42)	-	6.02
Gross deferred tax liabilities	7.44	(1.42)	-	6.02
B. Deferred tax Assets				
Lease liabilities	7.60	(0.45)	-	7.15
Property, plant and equipment and Intangible assets : Impact of difference between tax depreciation and depreciation / amortization charged for the purpose of financial reporting	36.37	(26.75)	-	9.62
Impact of expenditure charged to the statement of profit and loss in the current period but allowed for tax purposes on payment basis	29.19	22.03	(0.49)	50.73
Others	0.14	0.20	-	0.34
Gross deferred tax assets	73.30	(4.97)	(0.49)	67.84
C. Net deferred tax (Asset) / liabilities (A-B)	(65.86)	3.55	0.49	(61.82)



31 Earnings per share (EPS)

Basic EPS is calculated by dividing the profit/ loss for the year attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the years. Partly paid equity shares are treated as a fraction of an equity share to the extent that they were entitled to participate in dividends relative to a fully paid equity share during the reporting years. The weighted average number of equity shares outstanding during the years is adjusted for events such as bonus issue, bonus element in a rights issue, share split, and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding without a corresponding change in resources.

Diluted EPS is calculated by dividing the profit attributable to equity shareholders by the weighted average number of equity shares outstanding during the years plus the weighted average number of equity shares that would be issued on conversion of all the dilutive potential equity shares into equity shares.

The following table reflects the income and share data used in the basic and diluted EPS computations

Particular	For the year ended March 31, 2024	For the year ended March 31, 2023 (Restated)
Face value of equity shares (₹ per share)*	1.00	1.00
Earnings		
Profit for the year as per standalone statement of Profit and Loss for Basic EPS and Diluted EPS (₹ in Million) (a)	1,111.06	155.46
Shares		
Weighted average number of equity shares used for computing EPS (Basic) (b)*	22,536,600	22,501,207
Add: Weighted average number of potential equity shares on account of share warrants (refer note 15)*	14,708	14,708
Weighted average number of equity shares used for computing EPS (Diluted) (c)*	22,551,308	22,515,915
EPS- Basic (₹) (e=a/b)	49.30	6.91
EPS- Diluted (₹) (e=a/c)	49.27	6.90

* Subsequent to the balance sheet date, the Company has increased its authorised share capital. Further the Company has 'sub-divided' the shares into face value of ₹1 per share, has converted the share warrants and approved the bonus issue. Further, the effect of conversion of share warrants into equity shares and bonus issue has not been given to the accompanying standalone Ind AS financial statements. Refer note 48 for further details

32 Significant accounting judgements, estimates and assumptions

The preparation of the Company's Standalone Ind AS Financial Statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Actual results could differ from those estimates. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised and future periods affected.

Significant judgements and estimates relating to the carrying values of assets and liabilities include fair value measurement of financial instruments, contingencies, defined benefit plans (gratuity benefits), provision for expected credit losses of trade receivables, leases - estimating the incremental borrowing rate and impairment of investments.

The key assumptions concerning the future and other key sources of estimation uncertainty at the reporting date, that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are described below. The Company based its assumptions and estimates on parameters available when the Standalone Ind AS Financial Statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. Such changes are reflected in the assumptions when they occur.

(This space has been intentionally left blank)



Handwritten signature in blue ink.



32 Significant accounting judgements, estimates and assumptions (continued)

(a) Fair value measurement of financial instruments

When the fair values of financial assets and financial liabilities recorded in the Standalone Ind AS Balance Sheet cannot be measured based on quoted prices in active markets, their fair value is measured using valuation techniques including the DCF model. The inputs to these models are taken from observable markets where possible, but where this is not feasible, a degree of judgement is required in establishing fair values. Judgements include considerations of inputs such as liquidity risk, credit risk and volatility. Changes in assumptions about these factors could affect the reported fair value of financial instruments. Refer note 38 for further disclosures.

(b) Contingencies

Contingent liabilities may arise from the ordinary course of business in relation to claims against the Company, including legal and contractual claims. By their nature, contingencies will be resolved only when one or more uncertain future events occur or fail to occur. The assessment of the existence and potential quantum of contingencies inherently involves the exercise of significant judgement and the use of estimates regarding the outcome of future events. Refer note 35 for further disclosures.

(c) Defined benefit plans (gratuity benefits)

The cost of the defined benefit gratuity plan and the present value of the gratuity obligation are determined using actuarial valuations. An actuarial valuation involves making various assumptions that may differ from actual developments in the future. These include the determination of the discount rate, future salary increases and mortality rates. Due to the complexities involved in the valuation and its long-term nature, a defined benefit obligation is highly sensitive to changes in these assumptions. All assumptions are reviewed at each reporting date.

The parameter most subject to change is the discount rate. In determining the appropriate discount rate for plan operated in India, the management considers the interest rates of government bonds where remaining maturity of such bond correspond to expected term of defined benefit obligation. The mortality rate is based on publicly available mortality tables for India. Those mortality tables tend to change only at interval in response to demographic changes. Future salary increases and gratuity increases are based on expected future inflation rates for India.

Further details about gratuity obligations are given in note 33.

(d) Provision for expected credit losses of trade receivables and contract assets

The company estimates the credit allowance as per practical expedient based on the historical credit loss experience as enumerated in credit risk section of note 38.

(e) Leases - Estimating the incremental borrowing rate

The Company cannot readily determine the interest rate implicit in the lease, therefore, it uses its incremental borrowing rate (IBR) to measure lease liabilities. The IBR is the rate of interest that the Company would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The IBR therefore reflects what the Company 'would have to pay', which requires estimation when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. The Company estimates the IBR using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates. Refer note 34 for further disclosures.

(f) Impairment of investments

Determining whether investment are impaired requires an estimation of the value in use of the respective asset or the relevant cash generating units. The value in use calculation is based on DCF model. Further, the cash flow projections are based on estimates and assumptions which are considered as reasonable by the management.

(g) Property, plant and equipment

Property, plant and equipment represent a significant proportion of the asset base of the Company. The charge in respect of periodic depreciation is derived after determining an estimate of an asset's expected useful life and the expected residual value at the end of its life. The useful lives and residual values of Company's assets are determined by management at the time the asset is acquired and reviewed periodically, including at each financial year end. The lives are based on historical experience with similar assets as well as anticipation of future events, which may impact their life, such as changes in technology.

(h) Impairment of non-financial assets

Impairment exists when the carrying value of an asset or cash generating unit (CGU) exceeds its recoverable amount, which is the higher of its fair value less costs of disposal and its value in use. The fair value less costs of disposal calculation is based on available data from binding sales transactions, conducted at arm's length, for similar assets or observable market prices less incremental costs for disposing of the asset. The value in use calculation is based on a Discounted Cash Flow (DCF) model. The cash flows are derived from the budget and do not include restructuring activities that the Company is not yet committed to or significant future investments that will enhance the asset's performance of the CGU being tested. The recoverable amount is sensitive to the discount rate used for the DCF model as well as the expected future cash-inflows and the growth rate used for extrapolation purposes.

(i) Taxes

The Company uses estimates and judgements based on the relevant rulings in the areas of allocation of revenue, costs, allowances and disallowances which is exercised while determining the provision for income tax. Uncertainties exist with respect to the interpretation of tax regulations, changes in tax laws, and the amount and timing of future taxable income. Given the wide range of business relationships differences arising between the actual results and the assumptions made, or future changes to such assumptions, could necessitate future adjustments to tax income and expense already recorded. The Company establishes provisions, based on reasonable estimates. The amount of such provisions is based on various factors, such as experience of previous assessments and interpretations of tax regulations by the Company.

(j) Provision

Significant estimates are involved in the determination of provisions related to liquidated damages and warranty provision. Warranty provision is determined based on the historical trend of warranty expense for the same types of goods for which the warranty is currently being determined, after adjusting for unusual factors related to the goods that were sold or based on specific warranty clause in an agreement. Such estimates are reviewed annually for any material changes in assumptions and likelihood of occurrence. The provision for warranty and liquidated damages is based on the best estimate required to settle the present obligation at the end of reporting period.

(k) Provision for inventory obsolescence

Inventory obsolescence provision are determined using policies framed by the Company and in accordance with the methodologies that the Company deems appropriate to the business. There is a significant level of judgment involved in assessing whether provision for obsolescence for slow moving, excess or obsolete inventory items should be recognized considering orders in hand, expected orders, alternative usage, etc.

(This space has been intentionally left blank)



Handwritten signature.

Handwritten signature.



33 Gratuity and other post-employment benefit plans

I) Defined contribution plan

The Company's contribution to provident fund and other funds are considered as defined contribution plans. The contributions are charged to the Standalone Ind AS Statement of Profit and Loss as they accrue. Contributions to provident and other funds included in employee benefit expenses (refer note 26) are as under:

Particulars	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Contributions to provident fund	15.46	12.02
Total	15.46	12.02

II) Defined benefit plan

Gratuity

The Company has a defined benefit gratuity plan. The gratuity plan is governed by the Payment of Gratuity Act, 1972. Under the act, every employee who has completed five years or more of service gets gratuity on departure at 15 days salary (last drawn salary) for each completed year of service. The level of benefits provided depends on the member's length of service and salary at retirement age. The Gratuity plan is funded.

The following tables summarise the components of net benefit expenses recognised in the Standalone Ind AS Statement of Profit or Loss and amounts recognised in the Standalone Ind AS Balance Sheet for gratuity benefit:

i. Net benefit expenses (recognised in the Standalone Ind AS Statement of Profit and Loss)

Particulars	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Current service cost	4.76	4.01
Net interest expense	0.22	0.33
Net benefit expenses	4.98	4.34

ii. Remeasurement loss / (gain) recognised in other comprehensive income (OCI):

Particulars	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Actuarial loss / (gain) on obligations arising from changes in experience adjustments	0.84	(1.14)
Actuarial loss / (gain) on obligations arising from changes in financial assumptions	0.31	(0.71)
Actuarial loss / (gain) on arising from re-measurements on Plan Assets	0.13	(0.09)
Actuarial loss / (gain) recognised in OCI	1.28	(1.94)

(This space has been intentionally left blank)



6

1



33. Gratuity and other post-employment benefit plans (continued)

iii. Net defined benefit (liability) / asset

₹ in Million		
Particulars	March 31, 2024	March 31, 2023
Defined benefit obligation	(21.88)	(16.11)
Fair value of plan assets	15.17	10.83
Plan (liability) / asset	(6.71)	(5.28)
Non-current	(3.21)	(1.78)
Current	(3.50)	(3.50)

iv. Changes in the present value of the defined benefit obligation are as follows:

₹ in Million		
Particulars	March 31, 2024	March 31, 2023
Opening defined benefit obligation	16.11	13.95
Current service cost	4.76	4.01
Interest cost on defined benefit obligation	1.16	0.92
Benefits paid	(1.30)	(0.92)
Actuarial loss / (gain)		
Actuarial loss / (gain) on obligations arising from changes in experience adjustments	0.84	(1.14)
Actuarial loss / (gain) on obligations arising from changes in financial assumptions	0.31	(0.71)
Actuarial loss / (gain) on obligations arising from changes in demographic adjustments	-	-
Closing defined benefit obligation	21.88	16.11

v. Changes in the fair value of plan assets are as follows:

₹ in Million		
Particulars	March 31, 2024	March 31, 2023
Opening fair value of plan assets	10.83	7.73
Contributions by employer	4.83	3.34
Benefits paid	(1.30)	(0.92)
Interest income on plan assets	0.94	0.59
Return on plan assets, excluding interest income	(0.13)	0.09
Closing fair value of plan assets	15.17	10.83

vi. The major categories of plan assets as a percentage of the fair value of total plan assets are as follows:

Particulars	March 31, 2024	March 31, 2023
Investments with insurer	100%	100%

vii. The principal assumptions used in determining gratuity obligations for the Company's plan are shown below:

Particulars	March 31, 2024	March 31, 2023
Discount rate (in %)	7.00%	7.20%
Salary escalation rate (in %)	7.00%	7.00%
Employee turnover/ withdrawal rate	10.00%	10.00%
Retirement age	58 years	58 years
Weighted-average duration of the defined benefit obligation	6.5 years	6.5 years
Mortality rate	IALM 2012-14 (Ult)	IALM 2012-14 (Ult)

Notes:

a) The estimate of future salary increases, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors such as supply and demand factors in the employment market

b) Plan characteristics and associated risks

The Gratuity scheme is a Defined Benefit Plan that provides for a lump sum payment made on exit either by way of retirement, death, disability or voluntary withdrawal. The benefits are defined on the basis of final salary and the period of service and paid as lump sum at exit. The Plan design means the risks commonly affecting the liabilities and the financial results are expected to be

a) Discount rate risk - The defined benefit obligation calculated uses a discount rate based on government bonds. If bond yields fall, the defined benefit obligation will tend to increase

b) Salary Inflation risk - Higher than expected increases in salary will increase the defined benefit obligation

c) Demographic risk - This is the risk of variability of results due to unsystematic nature of decrements that include mortality, withdrawal, disability and retirement. The effect of these decrements on the defined benefit obligation is not straight forward and depends upon the combination of salary increase, discount rate and vesting criteria. It is important not to overstate withdrawals because in the financial analysis the retirement benefit of a short career employee typically costs less per year as compared to a long service employee

vii. A quantitative sensitivity analysis for significant assumption as at March 31, 2024 and March 31, 2023 is as shown below:

₹ in Million		
Particulars	March 31, 2024	March 31, 2023
Discount rate		
Impact on defined benefit obligation due to 1% increase in discount rate	(1.49)	(1.05)
Impact on defined benefit obligation due to 1% decrease in discount rate	1.71	1.21
Salary escalation rate		
Impact on defined benefit obligation due to 1% increase in salary escalation rate	1.70	1.20
Impact on defined benefit obligation due to 1% decrease in salary escalation rate	(1.50)	(1.06)
Attrition rate		
Impact on defined benefit obligation due to 1% increase in attrition rate	(0.17)	(0.13)
Impact on defined benefit obligation due to 1% decrease in attrition rate	0.17	0.13

The above sensitivity analysis is based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur and changes in some of the assumptions may be correlated. When calculating the sensitivity of the defined benefit obligation to significant actuarial assumptions the same method (present value of the defined benefit obligation calculated with the projected unit credit method at the end of the reporting period) has been applied as when calculating the defined benefit liability recognised in the Standalone Ind AS Balance Sheet. The sensitivity analysis may not be representative of an actual change in the defined benefit obligation as it is unlikely that changes in assumptions would occur in isolation from one another.

(This space has been intentionally left blank)



6

6



AL

34 Leases and commitments

a. Leases

Company as a lessee

The Company has lease contracts for office facilities/store premises, warehouses and lands. The lease term of the office facilities/store premises and warehouse is generally 1-5 years and the lease term of leasehold lands ranges from 30 to 99 years. The Company also has certain leases with lease term of 12 months or less (short term leases) or where the underlying asset is of low value. The Company has elected to avail the exemption and not to recognise right-of-use assets and lease liabilities for short term leases or the leases where the underlying asset is of low value.

The Company has lease contracts that include extension and termination options. The Company applies judgement in evaluating whether it is reasonably certain whether or not to exercise the option to renew or terminate the lease. That is, it considers all relevant factors that create an economic incentive for it to exercise either the renewal or termination. After the commencement date, the Company reassesses the lease term if there is a significant event or change in circumstances that is within its control and affects its ability to exercise or not to exercise the option to renew or to terminate (e.g., construction of significant leasehold improvements or significant customisation to the leased asset).

The carrying amounts of right-of-use assets recognised and the movements during the year is as follows:

Particulars	(₹ in Million)		
	Leasehold land	Building	Total
As at April 01, 2022	100.07	29.57	129.64
Additions	-	7.19	7.19
Depreciation	(2.58)	(10.28)	(12.86)
As at March 31, 2023	97.49	26.48	123.97
Additions	-	23.92	23.92
Termination of lease *	(31.65)	-	(31.65)
Depreciation	(2.31)	(14.64)	(16.95)
As at March 31, 2024	63.53	35.76	99.29

*During the current year, the Company has terminated the lease for a leasehold land taken from AMTZ and received the refund of advance lease payments.

The carrying amounts of lease liabilities assets recognised and the movements during the year is as follows:

	(₹ in Million)	
	March 31, 2024	March 31, 2023
Opening balance	28.41	30.18
Additions	23.51	7.04
Accretion of interest	2.77	2.80
Payments	(16.67)	(11.61)
Closing balance	38.02	28.41

The same is shown under:

Current	18.39	10.37
Non-current	19.63	18.04

The maturity analysis of lease liabilities are disclosed in note 38.

The effective interest rate for lease liabilities is 8.67% (March 31, 2023: 8.67%).

The following amounts are recognised in the Standalone Ind AS Statement of Profit and Loss

Particulars	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Depreciation expense of right-of-use assets (refer note 27)	16.95	12.86
Interest expense on lease liabilities (refer note 28)	2.77	2.80
Expense relating to leases of low-value assets/short term leases (included in other expenses)	6.08	7.09
Total amount recognised in the Standalone Ind AS Statement of Profit and Loss	25.80	22.75

The Company had total cash outflows for leases of ₹ 22.75 Million during the year ended March 31, 2024 (March 31, 2023: ₹ 18.70 Million).

b. Commitment

Particulars	(₹ in Million)	
	March 31, 2024	March 31, 2023
i) Estimated amount of contracts remaining to be executed on capital account not provided for, net of advances	107.22	9.69
ii) Refer note 15 pertaining to the terms / rights attached to share warrants		
iii) The Company has extended comfort letter to provide continued support to its subsidiaries to meet its debt and liabilities as they fall due and continue as going concern		

(This space has been intentionally left blank)



Handwritten signature.



35 Contingent liabilities

In the ordinary course of business, the Company faces claims and assertions by various parties. The Company assesses such claims and assertions and monitors the legal environment on an ongoing basis with the assistance of external legal counsel, wherever necessary. The Company records a liability for any claims where a potential loss is probable and capable of being estimated and discloses such matters in its Standalone Ind AS Financial Statements. If material. For potential losses that are considered possible, but not probable, the Company provides disclosure in the Standalone Ind AS Financial Statements but does not record a liability in its accounts unless the loss becomes probable.

The following is a description of claims and assertions where a potential loss is possible, but not probable. The Company believes that none of the contingencies described below would have a material adverse effect on the Company's financial condition, results of operations or cash flows.

Particulars	₹ in Million	
	March 31, 2024	March 31, 2023
i) Bank guarantees given by the Company	341.81	260.05
ii) Corporate guarantees given by the Company for loan taken by a subsidiary from lenders	600.00	-
iii) Matter relating to direct taxes under dispute ^{1, 2, 5}	-	0.30
iv) Matter relating to indirect taxes under dispute ²	126.56	59.19

1. Certain demands from the income tax authorities were set off against the brought forward business loss and depreciation of previous years which has not been disclosed above.

2. The amounts under disputes is as per the demands from the respective authorities for the respective periods and has not been adjusted to include further interest, penalty leviable, if any, at the time of final outcome of the appeals.

3. The Supreme court of India in the month of February 2019 had passed a judgement relating to definition of wages under the Provident Fund Act, 1952. The Management is of the view that there are interpretative challenges on the application of the judgement retrospectively. In the absence of reliable measurement of the provision for earlier periods, the Company has made a provision for provident fund contribution pursuant to the judgement only from the date of Supreme Court Order. The Company will evaluate its position and update its provision, if required, on receiving further clarity on the subject. The Company does not expect any material impact of the same.

4. The Company has received objections on certain trade mark applications on relative grounds of refusal under Section 11 of the Trade Mark Act, 1999 because the same/similar trade mark(s) is/are already on record of the register for the same or similar goods/services. The management of the Company is in the process of filing necessary replies and is confident of the outcome of the aforementioned trade mark applications to be favourable and accordingly no adjustments have been made in the Standalone Ind AS Financial Statements in this regard.

5. A search under Section 132 of the Income-tax Act, 1962 ("IT Act"), was carried out at the premises of the Company by the Income Tax authorities on March 11, 2024, followed by search closure visits on various dates during the year ended March 31, 2024 to check the compliance with the provisions of the IT Act. The income tax department has subsequently sought certain information / clarifications, which have been provided by being physically present in such meetings held. Management believes that the Company has complied with all the applicable provisions of the IT Act with respect to its operations. Further, during the year, the Company has paid an amount of ₹37.5 Million in connection with the search which has been classified under Non-current tax assets (net).

6. Also refer note 26.

(This space has been intentionally left blank)



[Handwritten signature]



36 Related party disclosures

a) Names of the related parties and description of relationship
Nature of Relationship

(i) Related party where control exists
Subsidiary Companies

Name of the Parties

Bigtec Private Limited (wholly owned)
Deciphar Life Sciences Private Limited (wholly owned)
Remfuel Bioenergy Private Limited (wholly owned)
Bigtec Healthcare Private Limited (wholly owned)
Prognosys Medical Systems Private Limited (Enterprise with common director upto February 28, 2023, subsidiary w.e.f. March 01, 2023)
Prognosys Healthcare Private Limited (w.e.f. July 26, 2023)

(ii) Entities on which significant influence exists

Chayagraphics (India) Private Limited (w.e.f. February 13, 2023)

(iii) Other related parties with whom transactions have been taken place during the year:

(a) Enterprise with common director

Coreintegra Global Services Private Limited

(b) Key managerial personnel

- Mr. Sriram Natarajan (CEO and Director)
- Mr. Chandrasekhar Bhaskaran Nair (Director)
- Mrs. Sangeetha Sriram (Director)
- Mr. Rohit Brijmohan Mantri (Director)
- Mr. Mulangi Krishnaswamy Ashokkumar (ceased to be director w.e.f. July 03, 2022)
- Mr. Rohit Ashok Kumar Mullangi (Director) (w.e.f. August 14, 2022)
- Mr. Ved Prakash Kalanoria (Director) (w.e.f. December 30, 2023)
- Mr. Suhas Ravindra Advant (Chief Financial Officer) (for the period May 08, 2023 to March 26, 2024)
- Mr. Amol Narayan Lone (Chief Financial Officer) (w.e.f. June 05, 2024)
- Mr. Darshan Raghunath Karekar (Company Secretary) (w.e.f. September 03, 2024)

(c) Relatives of key managerial personnel

- Mr. Shiva Sriram
- Mrs. Sarada Natarajan

(This space has been intentionally left blank)



6

1



12

36 Related party disclosures (continued)

The following table provides the total amount of transactions that have been entered into with related parties for the relevant financial year.

(b) Transactions with the above related parties during the year:

			(₹ in Million)	
			For the year ended March 31, 2024	For the year ended March 31, 2023
Transactions during the year				
Interest income on loan				
Prognosys Medical Systems Private Limited	Subsidiary Company		2.67	20.25
Bigtec Private Limited	Subsidiary Company		33.80	30.93
Purchase of traded goods				
Bigtec Private Limited	Subsidiary Company		0.40	0.16
Prognosys Medical Systems Private Limited	Subsidiary Company		54.00	-
Cost of raw material consumed				
Bigtec Private Limited	Subsidiary Company		0.91	-
Other expenses - Royalty expense				
Bigtec Private Limited	Subsidiary Company		739.28	315.96
Finance costs				
Mr. Sriram Natarajan	Director		1.56	28.73
Legal and professional charges				
Coreintegra Global Services Private Limited	Enterprise with common director		0.55	-
Expenses incurred on behalf of the Company				
Bigtec Private Limited	Subsidiary Company		1.04	1.93
Mr. Sriram Natarajan	Director		4.97	5.99
Mrs. Sangeetha Sriram	Director		0.01	-
Mr. Shiva Sriram	Relative of key managerial personnel		1.30	-
Loans taken				
Mr. Sriram Natarajan	Director		47.50	80.00
Loans repaid				
Mr. Sriram Natarajan	Director		122.58	447.33
Loans given				
Prognosys Medical Systems Private Limited	Subsidiary Company		130.00	40.00
Bigtec Private Limited	Subsidiary Company		417.50	483.04
Loans refunded				
Prognosys Medical Systems Private Limited	Subsidiary Company		80.00	240.00
Loans adjusted against trade payables				
Bigtec Private Limited	Subsidiary Company		539.99	360.55
Interest accrued adjusted against trade payables				
Bigtec Private Limited	Subsidiary Company		18.30	-
Investment in equity shares				
Prognosys Medical Systems Private Limited	Subsidiary Company		-	144.60
Prognosys Healthcare Private Limited	Subsidiary Company		102.62	-
Investment in compulsorily convertible preference shares				
Prognosys Medical Systems Private Limited	Subsidiary Company		-	246.11
Chayagraphics (India) Private Limited	Associate company		-	60.00
Remuneration				
Mr. Sriram Natarajan	CEO and Director		18.18	18.02
Mrs. Sangeetha Sriram	Director		2.40	2.42
Mr. Shiva Sriram	Relative of key managerial personnel		23.78	3.26
Mr. Suhas Ravindra Advant	Chief Financial Officer		7.43	-
Impairment on investments				
Remfuel Bioenergy Private Limited	Subsidiary Company		-	0.10
Bigtec Healthcare Private Limited	Subsidiary Company		-	0.05
Prognosys Healthcare Private Limited	Subsidiary Company		102.62	-

(This space has been intentionally left blank)



Handwritten signature in blue ink.



36 Related party disclosures (continued)

2) Outstanding balances as at year end

			(₹ in Million)	
			March 31, 2024	March 31, 2023
Balances payable to related parties are as follows:				
Current borrowings				
Mr. Sriram Natarajan	Director		0.37	73.89
Trade payables				
Bigtec Private Limited	Subsidiary Company		209.35	-
Coreintegra Global Services Private Limited	Enterprise with common director		0.08	-
Employee related payables				
Mr. Sriram Natarajan	Director		1.30	6.91
Mr. Shiva Sriram	Relative of key managerial personnel		25.35	20.25
Mrs. Sangeetha Sriram	Director		0.04	0.16
Balances receivable from related parties are as follows:				
Trade receivables				
Prognosys Medical Systems Private Limited	Subsidiary Company		0.59	0.76
Impairment allowance (allowance for bad and doubtful debts)				
Prognosys Medical Systems Private Limited	Subsidiary Company		(0.59)	-
Loan - Current (Unsecured)				
Prognosys Medical Systems Private Limited	Subsidiary Company		50.00	-
Bigtec Private Limited	Subsidiary Company		-	122.49
Interest accrued on loans given				
Prognosys Medical Systems Private Limited	Subsidiary Company		22.04	19.32
Bigtec Private Limited	Subsidiary Company		-	30.93
Advances other than capital advances - Current				
Bigtec Private Limited	Subsidiary Company		-	31.79
Impairment on investments				
Remfuel Bioenergy Private Limited	Subsidiary Company		0.10	0.10
Bigtec Healthcare Private Limited	Subsidiary Company		0.05	0.05
Prognosys Healthcare Private Limited	Subsidiary Company		102.62	-
Deciphar Life Sciences Private Limited	Subsidiary Company		0.11	0.11
Corporate Guarantee				
Prognosys Medical Systems Private Limited	Subsidiary Company		600.00	-

Notes

- The remuneration to the key managerial personnel does not include provisions made for gratuity and leave benefits, as they are determined on an actuarial basis for the Company as a whole.
- The above information has been determined to the extent such parties have been identified on the basis of information available with the Company.
- In respect of transactions with related parties, the Company has complied with the provisions of Section 188 of the Companies Act, 2013 where applicable, and the details have been disclosed above, as required by the applicable accounting standards.
- Details of loans under section 186(4) of the Companies Act, 2013

- During the year ended March 31, 2024

Name of loanee	Rate of interest	Due date	Secured / Unsecured	Purpose	At the beginning of the year	Loans given	Loans received back / adjusted with trade payables	At the end of the year
Prognosys Medical Systems Private Limited	10.00%	March 31, 2025	Unsecured	Utilising for making earnest money deposit for tenders and business purpose	-	130.00	(80.00)	50.00
Bigtec Private Limited	10.00%	March 31, 2026	Unsecured	Financial assistance for the purpose of carrying on its R&D activities	122.49	417.50	(539.99)	-

- During the year ended March 31, 2023

Name of loanee	Rate of interest	Due date	Secured / Unsecured	Purpose	At the beginning of the year	Loans given	Loans received back / adjusted with trade payables	At the end of the year
Prognosys Medical Systems Private Limited	10.00%	March 31, 2023	Unsecured	Utilising for making earnest money deposit for tenders and business purpose	200.00	40.00	(240.00)	-
Bigtec Private Limited	10.00%	March 31, 2024	Unsecured	Financial assistance for the purpose of carrying on its R&D activities	-	483.04	(360.55)	122.49



Handwritten signature in blue ink.



Handwritten signature in blue ink.

37 Segment information - Disclosure pursuant to Ind AS 108 'Operating Segments'

a) Basis of identifying operating segments:

An operating segment is a component that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the other components, whose operating results are regularly reviewed by the Company's Chief Operating Decision Maker (CODM) to make decisions about resource allocation and performance assessment and for which discrete financial information is available. The Company is engaged in the business of manufacturing chip based Diagnostic Devices, chips and reagents. Accordingly, the Company's activities and business is reviewed regularly by the chief operating decision maker from an overall business perspective, rather than reviewing its products / services as individual standalone components. Thus, the Company has only one operating segment, and has no reportable segment in accordance with Ind AS- 108 'Operating Segments'.

b) The Chief Operating Decision Maker ("CODM") of the Company for the year ended March 31, 2024 and March 31, 2023, has been identified as Board of Directors (BoD) of the Company.

(i) The entity wide disclosures as required by Ind AS-108 are as follows:

Particulars	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
Sale of products	7,425.32	3,165.37
Other operating revenue	137.83	100.35
Total	7,563.15	3,265.72

(ii) Geographical information

Revenue from customers

Particulars	(₹ in Million)	
	For the year ended March 31, 2024	For the year ended March 31, 2023
India	6,753.28	2,778.62
Outside India*	809.87	487.10
Total	7,563.15	3,265.72

*Exports to any single country are not material to be disclosed.

Non-current assets**

Particulars	(₹ in Million)	
	March 31, 2024	March 31, 2023
India	2,416.74	1,923.46
Outside India	-	-
Total	2,416.74	1,923.46

** Non-current assets does not include deferred tax assets, financial assets and non-current tax assets.

(iii) Revenue from two customers accounted for ₹ 3,571.66 Million which was more than 10% of total revenue of the Company during the year ended March 31, 2024. During the year ended March 31, 2023 no customers accounted for more than 10% of total revenue of the Company for the said year.

38 Disclosures on financial instruments

This section gives an overview of the significance of financial instruments for the Company and provides additional information on balance sheet items that contain financial instruments.

The details of significant accounting policies, including the criteria for recognition, the basis of measurement and the basis on which income and expenses are recognised in respect of each class of financial asset, financial liability and equity instrument are disclosed in accounting policy to the financial statements.

(a) Financial assets and liabilities

The management assessed that cash and bank balances, trade receivables, trade payables, and other current financial assets and liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Non-current financial assets and liabilities are discounted using an appropriate discounting rate where the time value of money is material.

The following tables presents the carrying value and fair value of each category of financial assets and liabilities as at March 31, 2024 and March 31, 2023

Particulars	(₹ in Million)	
	Carrying and Fair Value	
	March 31, 2024	March 31, 2023
Financial assets		
At Amortised cost		
(i) Loans	50.00	122.49
(ii) Trade receivables	3,602.55	1,733.11
(iii) Cash and cash equivalents	182.62	43.14
(iv) Bank balances other than cash and cash equivalents	-	2.64
(v) Other financial assets	267.30	435.84
At Fair value through profit and loss account		
(i) Investments	0.03	0.03
Total	4,102.50	2,337.25
Financial liabilities		
At Amortised cost		
(i) Borrowings	664.33	543.34
(ii) Trade payables	959.15	745.71
(iii) Lease liabilities	38.02	28.41
(iv) Other financial liabilities	96.09	103.98
Total	1,757.59	1,421.44

Notes:

1. As regards, carrying and fair value of investments in subsidiaries and associate refer note 6.

(This space has been intentionally left blank)



Handwritten signature in blue ink.



Handwritten signature in blue ink.

38 Disclosures on financial instruments (continued)

(b) Fair value hierarchy

Quoted prices in an active market (Level 1): This level of hierarchy includes financial assets that are measured by reference to quoted prices (unadjusted) in active markets for identical assets or liabilities.

Valuation techniques with observable inputs (Level 2): This level of hierarchy includes financial assets and liabilities, measured using inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices).

Valuation techniques with significant unobservable inputs (Level 3): This level of hierarchy includes financial assets and liabilities measured using inputs that are not based on observable market data (unobservable inputs). Fair values are determined in whole or in part, using a valuation model based on assumptions that are neither supported by prices from observable current market transactions in the same instrument nor are they based on available market data.

The following table provides an analysis of financial instruments that are measured subsequent to initial recognition at fair value, grouped into Level 1 to Level 3, as described below:

Particulars	Fair value measurements at reporting date using			
	Total	Level 1	Level 2	Level 3
March 31, 2024				
Financial assets				
Investments (at fair value through Profit and loss account)	0.03	-	-	0.03
Assets for which fair values are disclosed				
Investment property	418.70	-	-	418.70
Financial liabilities				
Borrowings (at amortised cost)	664.33	-	664.33	-
March 31, 2023				
Financial assets				
Investments (at fair value through Profit and loss account)	0.03	-	-	0.03
Financial liabilities				
Borrowings (at amortised cost)	543.34	-	543.34	-

(i) Short-term financial assets and liabilities including cash and cash equivalents, trade receivables, trade payables, bank overdrafts and other current liabilities are stated at carrying value which approximately equal to their fair value largely due to the short-term maturities of these instruments.

(ii) Management uses its best judgement in estimating the fair value of its financial instruments. However, there are inherent limitations in any estimation technique. Therefore, for substantially all financial instruments, the fair value estimates presented above are not necessarily indicative of the amounts that the Company could have realised or paid in sale transactions as of respective dates. As such, fair value of financial instruments subsequent to the reporting dates may be different from the amounts reported at each reporting date.

(iii) There have been no transfers between Level 1, Level 2 and Level 3 for the year ended March 31, 2024 and March 31, 2023.

(c) Financial risk management objectives and policies

The Company's principal financial liabilities comprise loans and borrowings, lease liabilities, trade and other payables. The main purpose of these financial liabilities is to finance the Company's operations. The Company's principal financial assets include trade receivables, other financial assets and cash and bank balances derived from its operations.

In the course of its business, the Company is exposed primarily to fluctuations in foreign currency exchange rates, interest rates, liquidity and credit risk, which may adversely impact the fair value of its financial instruments. The Company has a risk management policy which not only covers the foreign exchange risks but also other risks associated with the financial assets and liabilities such as interest rate risks and credit risks. The risk management policy is approved by the Board of Directors. The risk management framework aims to:

- create a stable business planning environment by reducing the impact of currency and interest rate fluctuations on the Company's business plan.
- achieve greater predictability to earnings by determining the financial value of the expected earnings in advance.

(i) Market risk

Market risk is the risk of any loss in future earnings, in realisable fair values or in future cash flows that may result from a change in the price of a financial instrument. The value of a financial instrument may change as a result of changes in interest rates, foreign currency exchange rates, liquidity and other market changes. Future specific market movements cannot be normally predicted with reasonable accuracy.

(This space has been intentionally left blank)



Handwritten signature in blue ink.



Handwritten signature in blue ink.

38 Disclosures on financial instruments (continued)

(1) Market risk- Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's exposure to the risk of changes in market interest rates relates primarily to the Company's debt obligations with floating interest rates. Thus profits and cash flows from financing activities are dependent on market interest rates. Further, any decline in the credit rating of the Company will have an adverse impact on the interest rates. The Company manages its interest rate risk by having a balanced portfolio of fixed and variable rate loans and borrowings.

The Company has interest-bearing assets in the form of cash and cash equivalents (current deposits). Thus profits and cash flows from investment activities are dependent on market interest rates. The Company does not earn any interest on balances with banks in current accounts and its daily operating accounts for transactions. During the year ended March 31, 2024, the Company's cash and cash equivalents (current deposits) earned an effective interest rate (referring to yield from time deposits and current accounts) amounting to 3.54% per annum (March 31, 2023: 5.14% per annum).

The interest rate profile of the Company's interest-bearing financial instruments as reported to the management of the Company is as follows:

Particulars	(₹ in Million)	
	March 31, 2024	March 31, 2023
Fixed rate instruments:		
Financial liabilities	250.46	71.49
Financial assets	205.98	392.42
Variable rate instruments:		
Financial liabilities	408.19	442.44

Interest rate sensitivity

The following table demonstrates the sensitivity to a reasonably possible change in interest rate on the portion of loans and borrowings affected. With all other variables held constant, the Company's profit before tax is affected through the impact on floating rate borrowings as following:

Particulars	Increase / decrease in basis points	(₹ in Million)	
		March 31, 2024	March 31, 2023
Interest rate fluctuation	+50	(2.04)	(2.21)
Interest rate fluctuation	-50	2.04	2.21

(2) Market risk- Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of an exposure will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily to the Company's operating and financing activities. The Company's exposure to foreign currency changes for currencies other than USD is not material.

The following table shows foreign currency exposure at the end of reporting year:

March 31, 2024

Particulars	Amount in rupees (in million) for USD
Financial Assets	
Impact on profit and loss:	
5% increase	2.26
5% decrease	(2.26)
Financial liabilities	
Impact on profit and loss:	
5% increase	(10.57)
5% decrease	10.57

March 31, 2023

Particulars	Amount in rupees (in million) for USD
Financial Assets	
Impact on profit and loss:	
5% increase	5.47
5% decrease	(5.47)
Financial liabilities	
Impact on profit and loss:	
5% increase	(11.14)
5% decrease	11.14

(This space has been intentionally left blank)



Handwritten signature in blue ink.



Handwritten signature in blue ink.

38 Disclosures on financial instruments (continued)

(ii) Credit risk

Credit risk is the risk that counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. Financial instruments that are subject to credit risk and concentration thereof principally consist of loan receivables, trade receivables, cash and cash equivalents, bank balances and other financial assets of the Company.

The carrying value of financial assets represents the maximum credit risk. The maximum exposure to credit risk was ₹ 4,640.41 Million (March 31, 2023: ₹ 2,875.16 Million), being the total carrying value of investments, loans receivables from related parties, trade receivables, cash and cash equivalents, bank balances and other financial assets of the Company.

Customer credit risk is managed based on the Company's established policy, procedures and control relating to customer credit risk management. An impairment analysis is performed at each reporting date on an individual basis for major customers. The Company does not hold collateral as security. Further, the top 5 customers of the Company contributes to more than 72% (March 31, 2023: 56%) of the trade receivables during the year ended March 31, 2024.

With respect to Trade receivables, the Company has constituted the terms to review the receivables on periodic basis and to take necessary mitigations, wherever required. The Company creates allowance for unsecured receivables based on historical credit loss experience and is adjusted for forward looking information. The allowance of trade receivables is based on the ageing of the receivables that are due.

Refer note 10 for movement in expected credit loss for the years ended March 31, 2024 and March 31, 2023.

Credit risk from balances with bank and financial institutions and in respect to loans and security deposits is managed by the Company's treasury department in accordance with the Company's policy. Investments of surplus funds are made only with approved counterparties and within credit limits assigned to each counterparty. The limits are set to minimise the concentration of risks and therefore mitigate financial loss through counterparty's potential failure to make payments.

In respect of financial guarantees provided by the Company to banks and loans obtained by the subsidiary company, the maximum exposure which the Company is exposed to is the maximum amount which the Company would have to pay if the guarantee is called upon. Based on the expectation at the end of the reporting period, the Company considers that it is more likely than not that such an amount will not be payable under the guarantees provided.

(iii) Liquidity risk

Liquidity risk refers to the risk that the Company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company has obtained fund based working capital limits from a bank. The Company invests its surplus funds in bank fixed deposit, which carry no or low market risk.

The Company monitors its risk of shortage of funds on a regular basis. The Company's objective is to maintain a balance between continuity of funding and flexibility through the use of bank overdrafts, bank loans, etc. The Company assessed the concentration of risk with respect to refinancing its debt and concluded it to be medium.

The following table shows a maturity analysis of the anticipated cash flows excluding interest obligations for the Company's financial liabilities on an undiscounted basis, which may differ from both carrying value and fair value:

Particulars	(₹ in Million)			
	0 - 1 years	1 to 5 years	> 5 years	Total
March 31, 2024				
Borrowings	513.10	152.36	-	665.46
Lease liabilities	20.95	14.86	23.29	59.10
Trade payables	959.15	-	-	959.15
Other financial liabilities	96.09	-	-	96.09
	1,589.29	167.22	23.29	1,779.80
March 31, 2023				
Borrowings	533.49	9.85	-	543.34
Lease liabilities	12.43	13.57	24.07	50.08
Trade payables	745.71	-	-	745.71
Other financial liabilities	103.98	-	-	103.98
	1,395.61	23.42	24.07	1,443.11

The above excludes any financial liabilities arising out of corporate guarantee given to subsidiary as disclosed in note 36.

(This space has been intentionally left blank)



6



39 Capital management

The Company's capital management is intended to create value for shareholders by facilitating the meeting of long-term and short-term goals of the Company. The Company determines the amount of capital required on the basis of annual business plan coupled with long-term and short-term strategic investment and expansion plans. The funding needs are met through equity, cash generated from operations, borrowings.

For the purpose of the Company's capital management, capital includes issued equity capital, and all other equity reserves attributable to the equity shareholders of the Company.

The Company manages its capital structure and makes adjustments in light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using a gearing ratio, which is total debt divided by total capital plus total debt. The Company's policy is to keep the gearing ratio at an optimum level to ensure that the debt related covenants are complied with.

Particulars	₹ in Million	
	March 31, 2024	March 31, 2023
Borrowings and lease liabilities (refer note 16 and 34)	702.35	571.75
Less: Cash and bank balances (refer note 12)	(182.62)	(45.78)
Total debt (A)	519.73	525.97
Equity share capital (refer note 14)	22.54	22.54
Other equity (refer note 15)	8,477.30	7,367.20
Total capital (B)	8,499.84	7,389.74
Capital and net borrowings & lease liabilities (C) = (A+B)	9,019.57	7,915.71
Gearing ratio (%) D= (A/C)	5.76%	6.64%

In order to achieve this overall objective, the Company's capital management, amongst other things, aims to ensure that it meets financial covenants attached to the interest-bearing loans and borrowings and lease liabilities that define capital structure requirements. Breaches in meeting the financial covenants would permit the bank to immediately call loans and borrowings.

No changes were made in the objectives, policies or processes for managing capital during the year ended March 31, 2024 and March 31, 2023.

(This space has been intentionally left blank)



Handwritten signature in blue ink.



Handwritten signature in blue ink.

40 Ratio Analysis and its elements

Particulars	Numerator	Denominator	March 31, 2024	March 31, 2023	Variance (March 2024 vs March 2023)	Explanation for Variance (March 2024 vs March 2023)
Current ratio	Current assets	Current liabilities	3.47	3.44	0.94% -	
Debt- Equity Ratio	Total borrowings (including lease liabilities)	Total equity	0.08	0.08	7.32% -	

Particulars	Numerator	Denominator	March 31, 2024	March 31, 2023	Variance (March 2024 vs March 2023)	Explanation for Variance (March 2024 vs March 2023)
Debt Service Coverage ratio	Earnings for debt service = Net profit after taxes + Non-cash operating expenses / (income) + Finance costs	Debt service = Finance costs + Lease Payments + Principal Repayments of borrowings	3.64	4.36	-16.55% -	
Return on Equity ratio	Net Profit after taxes	Average Total equity	0.14	0.02	533.25%	Increase is mainly due to increase in net profit after tax during the current year and increase in average equity on account of profits.
Inventory Turnover ratio	Cost of Goods Sold	Average Inventory	0.88	0.43	102.01%	Increase is mainly due to increase in consumption.
Trade Receivable Turnover Ratio	Revenue from operations	Average Trade Receivables	2.83	1.58	79.65%	Increase is mainly due to slow collection from trade receivables.
Trade Payable Turnover Ratio	Net Credit Purchases	Average Trade Payables	5.45	4.67	16.59%	
Net Capital Turnover Ratio	Revenue from operations	Working capital = Current assets - Current liabilities	1.46	0.75	93.36%	Increase is mainly due to increase in net profit after tax during the current year and increase in net working capital.
Net Profit ratio	Net profit after tax	Revenue from operations	0.15	0.05	205.48%	Increase is mainly due to increase in net profit after tax during the current year and increase in revenue from operations during the current year.
Return on Capital Employed	Earnings before interest and taxes	Capital Employed = Tangible Net Worth + Total Debt + Deferred tax liability / asset	0.18	0.04	387.15%	Increase is mainly due to increase in net profit after tax during the current year.
Return on Investment	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable	Not Applicable



CA



(This space has been intentionally left blank)

41 Details of CSR expenses:

a) Gross amount required to be spent by the Company during the year

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
56.14	52.04

b) Amount spent during the year ending March 31, 2024

- i) Constitution/acquisition of any asset
ii) On purposes other than (i) above

(₹ in Million)		
In Cash	Yet to be paid in cash	Total
-	-	-
-	-	-

c) Amount spent during the year ending March 31, 2023

- i) Constitution/acquisition of any asset
ii) On purposes other than (i) above

(₹ in Million)		
In Cash	Yet to be paid in cash	Total
-	-	-
-	-	-

d) Details related to spent / unspent obligations:

- i) Contribution to Public Trust
ii) Contribution to Charitable Trust
iii) Unspent amount in relation to:
- Ongoing project
- Other than Ongoing Project

(₹ in Million)	
For the year ended March 31, 2024	For the year ended March 31, 2023
-	-
-	-
56.14	-
-	52.04
56.14	52.04

e) Details of ongoing and other than ongoing project

March 31, 2024

(₹ in Million)							
Opening Balance		In case of S. 135(6) (Ongoing project)					
With Company	In Separate CSR Unspent A/c	Amount required to be spent during the year	Amount spent during the year		Closing Balance		
			From Company's bank A/c	From Separate CSR Unspent A/c	With Company	In Separate CSR Unspent A/c	Remarks
-	-	56.14	-	-	56.14	-	Refer note (f) below

March 31, 2024

(₹ in Million)					
In case of S. 135(5) (Other than ongoing project)					
Opening Balance	Amount deposited in Specified Fund of Sch. VII within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing Balance	Remarks
84.53	-	-	-	84.53	Refer note (g) below

March 31, 2023

(₹ in Million)							
Opening Balance		In case of S. 135(6) (Ongoing project)					
With Company	In Separate CSR Unspent A/c	Amount required to be spent during the year	Amount spent during the year		Closing Balance		
			From Company's bank A/c	From Separate CSR Unspent A/c	With Company	In Separate CSR Unspent A/c	Remarks
-	-	-	-	-	-	-	-

March 31, 2023

(₹ in Million)					
In case of S. 135(5) (Other than ongoing project)					
Opening Balance	Amount deposited in Specified Fund of Sch. VII within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing Balance	Remarks
32.49	-	52.04	-	84.53	Refer note (g) below

f) As per sub section (6) of Section 135 of the Companies Act, 2013 in respect of ongoing projects, the Company is required to transfer such unspent amount to a special account in any scheduled bank to be called as Unspent Corporate Social Responsibility Account within a period of thirty days from the end of the financial year. The Company has transferred the unspent amount of ₹ 56.14 Million in Unspent Corporate Social Responsibility Account after the due date on August 26, 2024.

g) As per sub section (5) of Section 135 of the Companies Act, 2013 in respect of other than ongoing projects, the Company is required to transfer such unspent amount to any fund as mentioned in schedule VII within six months from the end of the financial year, however till the date of these Standalone Ind AS financial statement the unspent amount for the year ended March 31, 2023 and earlier years has not been transferred to a fund specified in schedule VII to the Act.

(This space has been intentionally left blank)



42 Other Statutory information

(i) The Company does not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder.

(ii) The Company does not have any transactions with companies struck off during the year.

(iii) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period except for below

Nature of transaction	Location of Registrar of Company (ROC)	Period by which such charge had to be registered (in days or months)	Reason for delay in registration
2 - Vehicle term loans	ROC - Goa	30 days	Procedural delay
2 - Bank overdraft	ROC - Goa	30 days	Procedural delay, however subsequently rectified

(iv) The Company has not traded or invested in Crypto currency or Virtual Currency during the years ended March 31, 2024 and March 31, 2023.

(v) The Company has no such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961).

(vi) The Company has not been declared wilful defaulter by any bank, financial institution, government or government authority.

(vii) Following are the details of the funds advanced by the Company to Intermediaries for further advancing to the Ultimate beneficiaries:

Name of the intermediary to which the funds are advanced	Date of funds advanced	Amount of funds advanced (₹ in Million)	Date on which funds are invested by intermediaries to ultimate beneficiaries	Amount of funds further advanced to ultimate beneficiaries (₹ in Million)	Ultimate beneficiary
Chayagraphics (India) Private Limited	February 13, 2023	60.00	June 01, 2023	58.62	Shareholder of Chayagraphics Healthcare Private Limited

Complete details of the Intermediary and Ultimate Beneficiary.

Name of the entity	Registered address	Government Identification Number	Relationship with the Company
Chayagraphics (India) Private Limited	No 249, 1st Floor, Front Building 4th Main Road, Chamrajpet, Bangalore, Bangalore, Karnataka, India, 560018	U51507KA1996PTC021177	Associate

As detailed above, the Ultimate Beneficiaries is the shareholders of Chayagraphics Healthcare Private Limited from whom the Company through its step down subsidiary Chayagraphics (India) Private Limited have further acquired additional stake of Chayagraphics Healthcare Private Limited during the year.

(viii) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

- (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
- (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

43 Subsequent to the year ended March 31, 2024, the Company has identified amounting to ₹ 4.43 Million that frauds have been done against the Company by certain external parties. The Company has been deceived by the external parties by falsifying various documents and impersonating as the customer/vendor of the Company. Accordingly, the management has taken necessary legal actions including registration of first information report for the recovery of payments being made to illegitimate external parties.

44 As at March 31, 2024, trade and other payables amounting to ₹ 3.86 Million (March 31, 2023: ₹ 159.93 Million), advance from customers amounting to ₹ 12.16 Million and trade and other receivables amounting to ₹ 5.86 Million (March 31, 2023: ₹ 7.94 Million) towards purchase and sale of goods and services respectively, which are outstanding beyond permissible time period stipulated under the Master Circular on Import of Goods and Services and Master Circular on Export of Goods and Services issued by Reserve Bank of India ('the RBI'), which states that payments against imports of goods and receipts against exports of goods and services within defined regulatory timelines from date of shipment.

The management is in the process of regularising the above non-compliances, with the appropriate regulatory authorities and is of the view that penalties, if any that may be imposed on the Company would not be material. Accordingly, no adjustments have been made by the management in these standalone Ind AS financial statements in this regard.

(This space has been intentionally left blank)



Handwritten signature in blue ink.



Handwritten signature in blue ink.

45 Interest in significant investment in subsidiaries and associates as per Ind AS - 27

Name of the entity	Relationship as at		Percentage of effective ownership interest held (directly and indirectly) as at		Percentage of voting rights held as at		Date of incorporation	Country of incorporation/ place of business
	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023		
Bigtec Private Limited	Subsidiary	Subsidiary	100%	100%	100%	100%	July 03, 1996	India
Deciphar Life Sciences Private Limited	Subsidiary	Subsidiary	100%	100%	100%	100%	June 12, 2001	India
Remfuel Bioenergy Private Limited	Subsidiary	Subsidiary	100%	100%	100%	100%	November 25, 2008	India
Bigtec Healthcare Private Limited*	Subsidiary	Subsidiary	100%	100%	100%	100%	April 11, 2011	India
Prognosys Medical Systems Private Limited*	Subsidiary	Subsidiary	65.47%	65.47%	65.47%	65.47%	November 07, 2003	India
Prognosys Healthcare (India) Private Limited	Subsidiary	NA	54.54%	NA	54.54%	NA	February 27, 2015	India
Chayagraphics (India) Private Limited*	Associate	Associate	22.11%	22.11%	22.11%	22.11%	September 23, 1996	India

* Includes 50% shareholding held by Bigtec Private Limited in Bigtec Healthcare Private Limited

Includes investment in compulsory convertible preference shares in the nature of equity. Also refer note 6

46 MCA has amended the Rule 3 of the Companies (Accounts) Rules, 2014 (the "Accounts Rules") vide notification dated August 05, 2022, relating to the mode of keeping books of account and other books and papers in electronic mode. Back-ups of the books of account and other books and papers of the company maintained in electronic mode are now required to be retained on a server located in India on daily basis (instead of back-ups on a periodic basis as provided earlier) as prescribed under Rule 3(5) of the Accounts Rules. The Company is not in compliance with the above requirements and are in the process of initiating the necessary steps as regards the compliance with Rule 3 of the Companies (Accounts) Rules, 2014 with respect to backups taken on daily basis.

47 The Company has used certain accounting softwares for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software, except that, audit trail feature is not enabled for certain changes made, if any, to data using privileged/ administrative access rights in so far it relates to the aforesaid applications. Further, no instances of audit trail feature being tampered with respect to the above accounting software has been noted where audit trail has been enabled. Further, the Company has also used an accounting software which is operated by a third-party software service providers, for maintaining its books of account. Management is not in possession of necessary information to determine whether audit trail feature of the said software was enabled and operated throughout the year for all relevant transactions recorded in the software or whether there were any instances of the audit trail feature being tampered with during the year.

48 Subsequent Event

Subsequent to the year ended March 31, 2024 and pursuant to the approval of the Board of Directors and shareholders, as applicable under the provisions of Companies Act, 2013 and all other applicable laws and regulations :-

- The Company proposes to undertake an Initial Public Offering (IPO) of equity shares.
- The Company approved the share split of equity shares of the Company having a face value of ₹ 10 each into 10 equity shares having a face value of ₹ 1 each.
- The Company converted partially paid up share warrants into fully paid up share warrants. Fully paid up share warrants were then converted to fully paid up equity shares having a face value of ₹ 1 each.
- The Company approved the bonus issue of 11.28 Million equity shares of face value of ₹ 1 each for an amount aggregating to ₹ 11.28 Million (fully paid-up by way of capitalisation of the Company's free reserves/ securities premium account) to the existing equity shareholders of the Company. However the same has not been issued.

49 Certain amounts (currency value or percentages) shown in the various tables and paragraphs included in these Standalone Ind AS financial statements have been rounded off or truncated as deemed appropriate by the management of the Company.

As per our report of even date

For S R Batliboi & Associates LLP
Chartered Accountants
ICAI firm registration number: 101049W/ E300004
per Sandeep Kamani
Partner
Membership No: 061207
Place: Bengaluru
Date: September 30, 2024



For and on behalf of the Board of Directors of
Molbio Diagnostics Private Limited

Chandrasekhar Bhaskaran Nair
Director
DIN: 01787875
Place: Bengaluru
Date: September 30, 2024

Amol Narayan Lone
Chief Financial Officer

Place: Goa
Date: September 30, 2024

Sriram Natarajan
CEO & Director
DIN: 00013843
Place: Goa
Date: September 30, 2024

Darshan Karekar
Company Secretary
Membership number: ACS A45125

Place: Goa
Date: September 30, 2024

